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SUMMARY 
Neurocognitive impairment and social dysfunction has been reported in patients with 
bipolar disorder, and several studies have reported a relationship between neurocognition 
and social functioning in this group. Although some studies had suggested neurocognitive 
and social dysfunction in the early phases of bipolar disorder, there was little research on 
bipolar disorder patients diagnosed with a first manic episode at the planning of this thesis. 
The studies of social functioning in bipolar disorder had also been disadvantaged by the 
multitude of different assessment instruments in use. The first aim of study was therefore to 
establish reliability and validity of the Norwegian version of a well-known assessment 
instrument for social functioning – the Social Functioning Scale. The scale, originally 
developed for schizophrenia patients, was found to have good psychometric properties and 
was applicable for patients with bipolar disorder as well as for patients with schizophrenia. 
Although studies of neurocognition in the early phases of bipolar disorder were few, the 
existing literature had reported neurocognitive deficits in first-episode mania. Studies 
comparing neurocognitive functioning in first-episode patients to multiple-episode samples 
were few and inconclusive, and few studies had investigated to what degree first-episode 
patients showed clinically significant cognitive impairment. The second aim of the study was 
to describe neurocognitive functioning and the magnitude of dysfunction in a group of 
patients with first contact mania to an age, gender and education matched sample of 
healthy control participants. Patients were separated into two groups according to their 
number of previous manic episodes – one group consisting of patients with only one 
previous manic episode (First Manic episode; FM), and a second group with patients who 
had experienced multiple although untreated previous manic episodes (Previous manic 
episode; PM). Consistent with findings from two other studies of first episode mania patients 
we found statistically significant differences with moderate to large effect sizes between 
both patient groups and the healthy control group on measures of verbal recall, 
psychomotor speed, attention and some aspects of executive functioning as well as 
visuoconstructive reasoning. Psychomotor speed was the domain with the largest group 
differences. Eighteen percent of FM patients and sixteen percent of PM patients were 
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considered clinically significantly impaired across cognitive measures. Comparing the present 
findings to a non-overlapping sample of multiple-episode bipolar disorder patients from our 
study group suggests comparable dysfunction in some aspects of verbal recall and executive 
functioning, and consistently smaller deficits among the first-episode group on the 
remaining neuropsychological measures.  
Studies of social functioning in patients who have recently been hospitalized for a first manic 
episode have found that about half of this group experience social dysfunction even after 
remission of clinical symptoms. When planning this thesis, there were no previous studies 
that had examined the relationship between neurocognition and social functioning in first 
episode mania. The third aim of the study was therefore to investigate both self-rated and 
clinician-rated social functioning in first-episode mania, and the relationship between social 
functioning and neurocognition. We found that compared to a matched healthy control 
sample, patients with first-episode mania displayed statistically significantly poorer self-
rated social functioning on all subscales of the Social Functioning Scale. In addition, patients 
with previous untreated manic episodes rated themselves as being less competent in 
performing independent living skills, participated less in social activities, were less likely to 
be engaged in full-time employment and had a lower overall SFS score compared to patients 
with a first manic episode. There was also a relationship between a number of clinical 
measures and both self- and clinician-rated social functioning in the combined patient group. 
Depressive symptoms and processing speed had an independent contribution to self-rated 
social functioning, while psychotic symptoms significantly influenced clinician-rated social 
functioning.  
These findings suggest that neurocognitive dysfunction is present early in the course of 
bipolar disorder and reaches the level of clinical significance in a subgroup of individuals. 
Comparing our results with multiple-episode patients, the findings also suggest that the 
neurocognitive dysfunction may increase with illness progression. Results also show that 
impairment of social functioning in BD is present already after a first manic episode, and is 
associated with a number of clinical variables although depression had the largest influence 
on self-rated social functioning. Neurocognition, except from processing speed, did not 
appear to play a significant role in social functioning at this stage. Still, the findings underline 
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the importance of assessing neurocognitive functioning in patients with bipolar disorder 
early in the illness course, and suggest that at least a subgroup of patients might benefit 
from treatment aimed at enhancing cognitive functioning. As depressive symptoms were 
strongly related to social functioning, complete functional recovery after a depressive 
episode should therefore be the goal of treatment as well. 
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1. INTRODUCTION 
 
The essential feature of bipolar disorder (BD) is a clinical course that is characterized 
by periods of elevated mood and periods of depressed mood, in between periods of normal 
mood (euthymia). It is a severe mental illness that cause significant suffering and impaired 
functioning for the individuals affected by the disorder. Historically, mania and depression 
were first described by the ancient Greeks, but it was not until 1899 the term manic-
depressive insanity was used by Emil Kraepelin. Kraepelin segregated the two illnesses – 
manic depressive insanity (bipolar disorder) and dementia praecox (schizophrenia) – from 
another, placing special emphasis on the features of manic depressive insanity that 
differented it from dementia praecox; the periodic or episodic course, the more benign 
prognosis and a family history of manic-depressive insanity (Goodwin & Jamison, 2007). The 
description of a relatively good outcome in BD may have led to the expectation that patients 
with BD should have a rather normal functioning between episodes. As more research on 
neurocognition and social functioning in BD has been carried out during the last decade, 
there is now an increasing opinion that patients with BD experience a great deal of social 
and cognitive dysfunction also between illness episodes. Attempts to understand the brain’s 
role in BD began in earnest as clinically effective mood-altering drugs began to appear in the 
late 1950s and early 1960s. Over the next three decades, clinical studies attempted to 
uncover the biological factors mediating the pathophysiology of BD, including the 
measurement of neuropsychological functioning.  Traditionally, the research on deficits in 
neurocognition and social functioning associated with BD has been following in the footsteps 
of schizophrenia research. A Pub Med search on the terms cognition and bipolar disorder, 
versus cognition and schizophrenia, and social functioning and bipolar disorder, versus social 
functioning and schizophrenia, displays nearly six times as many published articles on 
cognition in schizophrenia than in BD, and five times as many articles written about social 
functioning in schizophrenia compared to BD. The differences between first-episode studies 
in schizophrenia and BD are even larger. While there were 2007 articles published on first 
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episode schizophrenia, and 1663 articles published on first episode psychosis, only 320 
articles on the search term first episode bipolar disorder were found in Pub Med. Studying 
first-episode BD patients may help us gain more knowledge about how the illness develops 
and progresses. It is for instance still uncertainty related to whether or not neurocognitive 
dysfunction in BD should be regarded as neurodevelopmental (i.e. born with) or 
neurodegenerative (i.e. progressive), and studies of patients early in the illness course might 
therefore facilitate to clarify some of the questions. 
Although schizophrenia research has been somewhat ahead of BD research, 
internationally there has been an increasing amount of research on BD (see for instance 
Akiskal, 2002; Angst, 2008; Berk, et al., 2009). In Norway, a growing amount of research on 
BD throughout the latest decade have included numerous areas such as insight (Engh et al., 
2007; Varga et al., 2006; 2007; 2009), substance abuse (Lagerberg et al., 2010a; 2011; Ringen 
et al., 2008), emotion perception (Aminoff et al., 2011; Vaskinn et al., 2007), age at onset 
(Larsson et al., 2010; Morken et al., 2009; Oedegaard et al., 2009), neurocognitive 
dysfunction in BDI and II (Andersson et al., 2008; Simonsen et al., 2008), genetics (Athanasiu 
et al., 2011; Djurovic et al., 2010; Kähler et al., 2010; Oedegaard et al., 2010; Tesli et al., 
2009), MRI (Hartberg et al., 2011) and social functioning (Simonsen et al., 2011). However, 
less is known about the early stages of BD, including neurocognitive functioning and social 
functioning. As a part of the ongoing translational research project Thematically Organized 
Psychosis research (TOP), this thesis have investigated neurocognitive functioning and social 
functioning in first-episode BD compared to healthy controls. The relationship between 
neurocognition and social functioning, and with clinical characteristics of the group have also 
been explored. 
Before describing the study that this thesis is based on, a brief description of DSM-IV bipolar 
I disorder (BD I) will be presented, along with a short description of neurocognition and 
psychosocial functioning in BD in general and in its early stages in particular. Some questions 
that needed answering at the planning of this thesis will also be discussed. 
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1.1. Clinical description of BD 
In the Diagnostic and Statistical Manual of Mental Disorders  (DSM-IV; American Psychiatric 
Association, 1994) BD is subgrouped into BD I, BD II, Cyclothymia and BD NOS. A BD I 
diagnosis may be given on the basis of manic episodes only, while in BD II, at least one 
hypomanic episode and one major depressive episode are required to fulfill diagnostic 
criteria. BD type I will be the focus of the present thesis. 
The DSM-IV main criterion for BD I is at least one manic episode that meet the following 
criteria: a distinct period of abnormally and persistently elevated, expansive, or irritable 
mood, lasting at least 1 week (or any duration if hospitalization is necessary). During the 
period of mood disturbance, at least three of the following symptoms should be present: 
inflated self-esteem or grandiosity; decreased need for sleep; being more talkative than 
usual or pressure to keep talking; flight of ideas or a subjective experience of racing 
thoughts; distractability; increase in goal-directed activity or psychomotor agitation; and/or 
excessive involvement in pleasurable activities that have a high potential for painful 
consequences. Mood symptoms also have to cause clinically significant distress or 
impairment in social, occupational, or other important areas of functioning.  
Psychosis can occur in both manic and depressed states in BD I. In a review of 33 studies, 
Goodwin and Jamison (2007) concluded that approximately two-thirds of patients with BD 
had a lifetime history of at least one psychotic symptom, more often during manic episodes. 
In a manic episode, grandiose delusions are the most common type of psychotic symptom, 
but any kind of psychotic symptom including thought disorder, hallucinations, mood-
incongruent psychotic symptoms and catatonia can present as part of an episode 
(Dunayevich and Keck, 2000). 
The lifetime prevalence rates of BD across countries ranges from 0.3 to 1.5 % (Weissman et 
al., 1996). Sherazi et al (2006) reviewed 18 studies and found a prevalence of BD I ranging 
from 0.1 to 1.8 %, however they suggest that studies may have overestimated prevalence of 
mania and underestimated incidence, and that incidence of mania may be increasing in later 
generations. In Norway, a large-scale psychiatric epidemiologic study of Oslo reported the 
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lifetime prevalence for BD to be 1.6% with an annual prevalence of 0.9% (Kringlen et al., 
2001). 
 
 
1.1.1. The early phases of BD 
There has been a paucity of studies on early phases of BD, especially compared to the 
growing interest devoted to the early phase of other severe mental illnesses such as 
schizophrenia. Studies have provided considerable support for the importance of stressful 
life events in the onset of episodes (Hunt et al., 1992; Johnson and Miller, 1997) and the 
influence of life events triggering mood episodes is allegedly more prominent in earlier than 
in later phases of BD. The prodromal phase of BD before a first episode onset may be 
characterized by high levels of stress, suicide attempts, anxiety disorders and alchohol or 
substance abuse (Azorin et al., 2011; Winokur et al., 1998).  
Data from 15 studies published after 1990 have reported an average age at onset of 22.2 
years for BD (Goodwin and Jamison, 2007). Results from the TOP study group reported a 
mean onset at age 22.8, with 38% of BD patients having an early onset before age 18 
(Larsson et al., 2010). Earlier onset of BD may be an important predictor of a more severe 
clinical course and poorer outcome (Carlson et al., 2000). 
Both the detection and treatment of BD is often delayed. Berk and colleagues (2007) 
reported a median age of 24 at first medical treatment, but the correct diagnosis of BD was 
not achieved until patients were 30 years. A treatment delay of nearly nine to ten years has 
also been reported (Altamura et al., 2010; Goldberg and Ernst, 2002). Since about half of BD 
patients may experience one or more major depressive episodes before their first episode of 
opposite polarity (Perugi et al., 2000) it is not possible to diagnose BD correctly until they 
develop the first manic or hypomanic episode. Manic episodes may also often be atypical, 
mixed or dysphoric during adolescence or early adulthood (Berk et al., 2007) which makes 
recognition of manic episodes even more challenging. The future of early intervention in BD 
depends thus on a correct identification of individuals at risk for developing BD, and the 
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capacity to provide targeted treatment that specifically prevents onset or recurrence of 
episodes (Salvadore et al., 2009). Early initiation of appropriate therapy is important not only 
to improve clinical outcome but also to prevent sequela of untreated illness including 
negative impacts on family relationships, psychosexual and vocational development, identity 
and a concept of self (Berk et al., 2009). 
The term first contact mania will be used in this thesis to describe the clinical sample, but 
other terms such as first episode BD and first manic episode will also be used 
interchangeably to describe patients in their early stages of the disorder. 
 
1.2. Neurocognition in BD 
Neurocognition is a term that is used in BD research amongst others, for what is traditionally 
called neuropsychology or cognition. Neuropsychological function is a term used to describe 
cognitive function in clinical groups, and covers a range of central cognitive functions or 
domains such as general intellectual functioning, attention, psychomotor speed, learning, 
memory and executive function. The contribution of traditional neuropsychological testing 
to our understanding of BD pertain several issues. Firstly, to provide an empirical basis for 
and clarification of clinical phenomenological concepts. Secondly, to determine which 
abnormalities are state dependent and which are state independent. Thirdly, to characterize 
the neuropsychological functions that appear to be most persistently impaired, providing a 
clue to pathophysiology. Finally, to determine the burden of the illness and its treatment 
with respect to cognitive functioning in terms of both cross-sectional and longitudinal 
outcomes. 
Meta-studies of neurocognition in BD have demonstrated deficits on standardized 
neuropsychological measures within domains involving executive functioning, verbal 
learning and memory, attention and processing speed (Bora et al., 2009; Jamrozinski, 2010; 
Kurtz and Gerraty, 2009; Robinson et al., 2006; Torres et al., 2007;). A number of studies 
emphasize the role of mediating factors for cognitive functioning in BD, for instance, how 
neurocognitive impairment is associated with clinical factors related to the illness. Number 
of episodes suffered (El-Badri et al., 2001), the number of hospital admissions (Martinez-
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Aran et al., 2004; Rubinsztein et al., 2000; Thompson et al., 2005) and duration of illness 
(Cavanagh et al., 2002; Clark et al., 2002; Martinez-Aran et al., 2004; Thompson et al., 2005), 
alcohol abuse (Holmes et al., 2009; Sanchez-Moreno et al., 2009), depressive symptoms 
(Malhi et al., 2004), manic symptoms (Strakowski et al., 2010) and history of psychosis 
(Simonsen et al., 2011) have all been related to neurocognitive impairment. The effect of 
antipsychotic medication on neurocognitive functioning may also be significant (Dittmann et 
al., 2008; Jamrozinski et al., 2009), particularly polypharmacy (Balanza-Martinez et al., 2010). 
However, a number of meta-analysis report neurocognitive deficits in individuals with BD 
also during euthymic states (Bora et al., 2009; Robinson et al., 2006; Torres et al., 2007), 
which challenges the former idea that impairment is transient and limited to the acute 
phases of the illness. 
The majority of studies have focused on the average neurocognitive performance of a BD 
group compared to a healthy control group, but fewer have investigated how many 
individuals with BD have so called clinically significant cognitive impairment, i.e. impairments 
that are so severe that one would expect it to have an impact on everyday life. The 
proportion of patients that have clinically significant cognitive impairment is variable, and 
depends on the particular task employed. Studies have reported clinically significant 
impairment (i.e. < 1.5 SD below control group mean or scoring below the 5th percentile, 
respectively) varying from 3-36% (Simonsen et al., 2008) and 3.2-41.9% (Thompson et al., 
2005), suggesting that more than half of people with BD do not experience cognitive 
difficulties or experience it only at a subclinical level. 
The etiology of cognitive dysfunction in BD is probably multifactorial, including gene-
environment interactions (Balanza-Martinez et al., 2010). A number of neurocognitive 
domains have been suggested as cognitive endophenotypes for BD. Endophenotypes should 
be associated with illness, they should be heritable and they should co-segregate within 
families with the illness (Bora et al., 2009). Studies of relatives to patients with BD have 
found deficits in verbal learning/memory, working memory (Balanza-Martinez et al., 2008) 
as well as response inhibition deficits (Bora et al., 2008) and these deficits are thus 
suggested as possible endophenotypes for BD. Findings from schizophrenia research indicate 
that processing speed deficits also may be central to several mental disorders (Dickinson et 
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al., 2007). Impairments in working memory and verbal learning has been linked to 
processing speed in schizophrenia (Leeson et al., 2010) and bipolar disorder (Kieseppä et al., 
2005) which adds to a growing body of research demonstrating the importance of 
processing speed for cognitive functioning and clinical outcome in severe mental disorders. 
The available MRI literature indicates that specific structural brain abnormalities are already 
present around the time of illness onset (Vita et al., 2009), and also in unaffected family 
members of patients with BD (Hajek et al., 2005). A number of MRI studies on first episode 
BD have demonstrated a pattern of brain abnormalities similar to the most replicated 
findings detected in samples of chronic patients, that is, enlargement of the ventricular 
system (Strakowski et al., 1993), smaller area of the corpus callosum (Atmaca et al., 2007), 
and the presence of brain white matter hyperintensities (Zanetti et al., 2008). Other MRI 
studies have reported significantly different cortical and subcortical brain abnormalities at 
illness onset that are not detected consistently in chronic patients, such as decreased 
volumes of frontal lobe and temporal gyrus gray matter (Farrow et al., 2005), reduction in 
neocortical (Nakamura et al., 2007) and cingulated gyrus (Farrow et al., 2005; Yatham et al., 
2007) gray matter volume, smaller amygdala volume (Rosso et al., 2007), and larger than 
normal striatum (Strakowski et al., 2002). These findings support the hypothesis of different 
changes in brain morphology over the time course of BD.  
Evidence for progressive cognitive decline in BD is still inconclusive. There is however some 
agreement that a neurodegenerative model may be appropriate for deficits in at least some 
cognitive domains (Goodwin et al., 2008). Whether the neurocognitive deficits reflects a 
widespread dysfunction or is a consequence of a primary deficit in a core cognitive 
functioning is unknown. 
 
1.2.1. Neurocognitive functioning in first-episode BD 
Although studies of neurocognition in first episode BD are few, their results suggest that 
neurocognitive deficits is present early in the course of the disorder. Studies comparing first-
episode BD patients to schizophrenia spectrum first-episode psychosis patients have either 
found less severe cognitive dysfunction in BD (Hill et al., 2009; Zanelli et al., 2010) or no clear 
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group differences (Barett et al., 2009; Zabala et al., 2010). Executive dysfunction in first-
episode BD compared to healthy controls has been reported in two studies (Fleck et al., 
2008; Gruber et al., 2008).  
A study from 2006 assessing neurocognition in 16 euthymic BD I patients who had recently 
received in- or outpatient treatment for a first manic episode, compared to 30 multiple-
episode BD I patients, found that the performance of the first-episode patients were 
significantly worse than the multiple-episode patients on tests of executive functions, 
sustained attention and perceptuomotor function (Nehra et al., 2006). The finding is 
somewhat contrary to expectations, but may be due to differences in demographic variables 
between the two groups, as patients in the first-episode group had for instance more 
psychotic symptoms and less education than the multiple-episode group. Torres et al (2010) 
reported moderate effect size differences between 45 euthymic BD I participants who had 
recently experienced their first manic episode compared to healthy comparison subjects on 
tasks assessing multiple cognitive domains, including sustained attention, learning and 
memory, and nonverbal/spatial reasoning. The percentage of patients showing cognitive 
impairment (i.e. scoring more than 1.5 SD below the mean of the control group) ranged from 
11-31% (Torres et al., 2010). When comparing the data to previously published meta-studies 
of multiple-episode euthymic BD samples (Robinson, 2006; Torres, 2007) results 
demonstrated that the magnitude of cognitive impairment in first-episode BD might be 
comparable to multiple-episode BD on tasks that included premorbid/verbal intellectual 
ability and attention/processing speed.  
 
 
1.3. Social functioning in BD 
The term social/psychosocial functioning is here used to cover functioning in different 
aspects of daily living. In schizophrenia research, functional outcome is a more frequently 
used overall term for the above aspects of daily living (Green, 2006).  The more general 
terms of psychosocial functioning, functional outcome and functioning will to some extent 
be used interchangeably in this thesis. Functioning is a complex term but will for the most 
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part involve different domains such as the capacity to work or study, the capacity to live 
independently, the capacity for recreation, and the capacity for romantic life (Zarate et al., 
2000). There are many different ways to measure social functioning, and the field has been 
disadvantaged by the use of a multitude of different assessment instruments that vary in 
their capacity to capture the heterogeneity of this area. In their review, Burns and Patrick 
(2007) found that the most frequently used social functioning scales in the assessment of 
schizophrenia were the Global Assessment of Function (GAF; American Psychiatric 
Association, 1994), the Global Assessment Scale (GAS; Endicott et al., 1976) and the Social 
Functioning Scale (SFS; Birchwood et al., 1990), respectively. Measurement of psychosocial 
outcome, particularly self-report assessment, have been controversial in the psychiatric 
literature (Smith et al., 1997) as patients’ illnesses might distort their abilities to self-report.  
Although Kraepelin described a relatively good outcome of manic-depressive illness 
(Kraepelin, 1921), it has subsequently been recognized that some patients with BD 
experience a poor outcome. In fact, BD has been associated with significant impairment in 
work, family and social life, beyond the acute phases of the illness (Sanchez-Moreno et al., 
2009). In a review from 2001 (MacQueen et al., 2001) between 30-60% out of 1450 patients 
with BD had detectable levels of social impairment, with impairments occurring in both 
occupational and social realms. BD has a negative effect on employment and productivity at 
work. A report from the National Comorbidity Survey Replication (NCS-R) based on 3.378 
workers in the US (Kessler and Merikangas, 2004) revealed that bipolar disorder was 
associated with 65.5 lost workdays per ill worker per year, which was substantially more 
than in major depressive disorder (27.2 lost workdays per ill worker per year) (Kessler et al., 
2006). The National Institute of Mental Health Collaborative Depression Study (NIMH-CDS) 
assessed 158 patients with BD I during 15 years and found that they were completely unable 
to carry out work role functions during  30% of the assessed months including symptom-free 
(euthymic) periods, which was significantly more than for unipolar major depressive disorder 
or BD II comparison subjects (Judd et al., 2008). In every country where statistics are 
available, the percentage of unemployed persons with BD is significantly above the mean 
level of unemployment (Morselli et al., 2004). One Norwegian study that investigated the 
relationship between length of education and social and occupational functioning in BD, 
found that BD patients had the same level of education but significantly lower social and 
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occupational function than the general population, and that BD was significantly associated 
with single status, low annual income and being on disability pension (Schoeyen et al., 2010).  
Studies of patients with BD have found a gap between syndromal recovery (i.e. no longer 
meeting the criteria for an ongoing DSM illness episode) and functional recovery. A large 
prospective study of remission and functional recovery in 1656 patients with BD I reported 
that functional recovery occurred in approximately half of those who achieved remission 
after 2 years (Haro et al., 2010). Studies of patients hospitalized for a first manic episode 
have found similar results. Keck, McElroy, Strakowski et al (1998) found that although 
syndromal recovery occurred in 48% of patients hospitalized for a first manic or mixed 
episode of BD, functional recovery occurred in only 24% of patients. The McLean/Harvard 
first-episode mania project found that functional recovery by six- and twenty-four months 
was nearly three times less likely than syndromal recovery; and 63 % of those recovering 
syndromally did not recover functionally by 2 years (Tohen et al., 2000). A prospective study 
from the Systematic Treatment Optimization Program for Early Mania (STOP-EM) showed 
that within 6 months of a first manic episode, 88.6% of patients had met criteria for 
remission of manic symptoms, but 25.7% showed at least moderate disability of functioning 
(Kauer-Sant’Anna et al., 2009).  
The most common clinical factors associated with impaired social functioning are related to 
depressive- or subsyndromal depressive symptoms (Bonnin et al., 2010; Fagiolini et al., 2005; 
Kauer-Sant'Anna, Bond, Lam, & Yatham, 2009; Martino et al., 2009; Mur et al., 2009; Pope, 
Dudley, & Scott, 2007; Simon et al., 2007). Episodes of depression have been associated with 
greater impairment in work, family and social life than episodes of mania (Calabrese et al., 
2004; Rosa et al., 2010). Poor functional outcome in BD has also been associated with a 
number of other clinical factors such as psychosis (Tohen et al., 1992), number of past 
episodes (MacQueen et al., 2000), hospitalizations (Ozer et al., 2002; Strakowski et al., 1998) 
and age at onset (Meeks, 1999; Perlis et al., 2009; Tsai et al., 2001), amongst others. 
One important question is whether or not the psychosocial functioning in BD 
becomes impaired after onset of the first episode, or if there are signs of poor functioning 
already before this. In schizophrenia, retrospective studies has shown poor premorbid 
adjustment among patients who later developed the disorder (Larsen et al., 1996). Cannon 
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et al (1997) reported that adult-onset BD patients had significantly poorer overall and 
adolescent premorbid adjustment than normal controls and that they did not differ from a 
schizophrenia comparison group on sociability. However a later study could not confirm this 
finding (Uzelac et al., 2006).  Goldberg and Ernst (2004) found that poor premorbid 
adjustment during childhood or adolescence tended to be related to co-occurring alcohol 
and substance abuse and an increased risk of suicide attempts in adult BD patients.  
 
1.4. The relationship between neurocognition and social functioning in BD 
Although clinical symptoms have been found to affect social functioning, several studies 
have also reported various areas of neurocognitive functioning to be independent correlates 
of social functioning. Neurocognition has been found to be significantly associated with 
psychosocial functioning in 6 of 8 studies of euthymic BD participants, and in 5 of 5 studies of 
non-euthymic BD samples (Wingo, Harvey, & Baldessarini, 2009). Various areas of 
neurocognition such as verbal memory (Altshuler et al., 2008; Bonnin et al., 2010; Martinez-
Aran et al., 2007; Martino et al., 2009), attention (Martino et al., 2009), executive 
functioning (Altshuler et al., 2008; Bonnin et al., 2010; Martinez-Aran et al., 2007; Martino et 
al., 2009) and processing speed (Mur et al., 2009) are all linked to social functioning, and 
have also been reported to predict long-term functional outcome in BD patients. Soft 
neurological signs (especially frontal signs) have also been reported to correlate strongly 
with social functioning (Goswami et al., 2006). Cognitive abilities including memory, planning 
or problem solving strategies and the emotional processing of information or social 
cognition are probably needed to cope satisfactory with the different psychosocial 
situations, and difficulty remembering long-term information may represent a serious 
problem for BD patients in their occupational functioning as well as in their interpersonal 
relationships (Sancez-Moreno et al., 2009). 
Studies concerning the relationship between neurocognition and social functioning in first-
episode BD patients are few. Torres et al (2010) studied the impact of cognitive functioning 
on longitudinal 6-month functional and clinical outcome in 45 (of 53) recently diagnosed 
clinically stable patients with BD I. Memory, particularly verbal learning/memory, was 
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robustly associated with 6-month functional outcome on a functioning scale, even after 
partialling out the influence of mood symptoms and substance abuse co-morbidity. There 
was however, a surprising lack of association between baseline cognitive functioning and 
concurrent baseline psychosocial functioning. 
 
1.5. Unanswered questions 
When the work on this thesis started out, there was little research on neurocognitive 
functioning in the early stages of bipolar disorder, although some studies with small samples 
had reported neurocognitive dysfunction early in the illness course. Questions that needed 
further investigation were for instance: do first-episode BD patients have specific or general 
cognitive deficits, are the deficits comparable to those found in multiple-episode BD 
patients, and how many patients have clinically significant cognitive impairment? 
The possible relationship between clinical characteristics, neurocognition and social 
functioning had up until then not been investigated in first manic episode BD. At present, 
there is still only one published study that examines the relationship between 
neurocognition and social functioning in first-episode BD. There was therefore a need to 
investigate this relationship further in a sample of patients with first-episode mania.  
One of the study’s aims was to investigate social functioning using a rating-scale that 
captured several aspects of social functioning. In order to achieve this, the Social Functioning 
Scale needed to be validated in its Norwegian version. Premorbid functioning and the 
relationship with current social functioning also needed investigation. 
Finally, since the first contact mania group was divided into two subgroups based on the 
number of previous manic episodes, possible group differences in neurocognition and/or in 
social functioning would also be of interest for this thesis.  
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2. AIMS OF THE THESIS 
Paper I 
Paper I had three aims: Firstly, to establish the reliability and validity of the Norwegian 
version of the Social Functioning Scale (SFS), and secondly, to investigate if the scale, 
originally developed for patients with schizophrenia, could be used for patients with bipolar 
disorder and healthy control subjects. Finally, the last aim was to examine social functioning 
in patients with bipolar disorder compared to patients with schizophrenia and healthy 
control subjects. 
 
Paper II 
The first aim of paper II was to describe neurocognitive functioning in the two BD subgroups 
(FM and PM) compared to an age, gender and education matched sample of healthy control 
participants, with a particular emphasis on the magnitude of cognitive deficits and number 
of clinically impaired cases within the cognitive domains. In addition we aimed to investigate 
if group differences could be explained by impaired processing speed. The second and 
specific aim of the paper was to examine if cognitive impairments were related to 
premorbid- and early illness characteristics, in particular age at onset, duration of untreated 
illness and number of episodes (manic, depressive and psychotic) prior to first treatment for 
BD. This might be helpful to the understanding of neurocognitive dysfunction in BD as trait- 
or state related, or a combination of both. 
 
Paper III 
The aims of paper III was firstly, to provide a comprehensive characterization of social 
functioning in the two BD subgroups (FM and PM) compared to healthy controls, using both 
clinician-rated and self-report measures. The second aim was to examine the relationship 
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between current self-reported and clinician-rated social functioning and neurocognition, age 
at onset, premorbid adjustment and clinical symptoms. 
 
3. METHODS 
3.1. Setting 
The present study is a naturalistic, cross-sectional study of patients coming to their first 
treatment for a manic episode (first contact mania), conducted within the framework of the 
Thematically Organized Psychosis (TOP) study group and the Regional Psychosis Research 
Network. The TOP study is a large, ongoing translational research study with the main aim of 
investigating clinical and biological characteristics of psychotic disorders to gain more 
knowledge about the pathophysiological mechanisms related to clinical, biological and 
environmental aspects of BD, schizophrenia and related psychotic disorders. The study 
group is affiliated with the University of Oslo, Oslo University Hospital (Ullevål University 
Hospital, Rikshospitalet, Aker University Hospital), Lovisenberg – Diakonhjemmet hospital 
and through the regional network to two large hospitals outside of Oslo (Innlandet Hospital 
and Akershus University Hospital).  
Patient inclusion to the TOP study started in October 2002, and is still ongoing, recruiting 
patients within diagnostic groups that are being treated in the psychiatric services at the 
participating hospitals. The study’s clinical assessment team involved in patient inclusion 
collaborates closely with the clinical staff in the psychiatric units. The Norwegian mental 
health care system has a catchment area patient admittance system, which offers public 
mental health care to all individuals with mental illness within a given catchment area, 
resulting in a relatively high degree of representativity for study participants. Healthy control 
participants were randomly selected from national statistical records from the same 
catchment area and contacted by letter inviting them to participate. 
The study is approved by the Regional Committee for Medical Ethics, Norwegian Data 
Inspectorate. The data file received an Audit Certificate from the Center for Clinical Research 
at Ullevål University Hospital in 2007. 
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Participants gave written informed consent to enter the study after receiving a complete 
description of the study. 
 
 
3.2. Participants 
Patients included in the current thesis were recruited from the psychiatric units (in- and 
outpatient) of the three major hospitals in Oslo and from Akershus University Hospital in the 
period of 2002 – 2010. This study uses two different samples. The samples used in paper II 
and III are identical, and differs from the sample used in study I. 
 
Table I: Total number of participants across papers 
 First contact 
mania (PM + 
FM) 
 
Bipolar 
spectrum 
disorders 
Schizophrenia 
spectrum 
disorders 
Healthy 
controls 
Data collection 
Paper 1 -- 100 100 100 October 2002 – 
September 2008 
Paper 2 55 -- -- 110 May 2006 – June 
2010 
Paper 3 55 -- -- 110 May 2006 – June 
2010 
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Table II: Demographical and clinical data of the samples used in paper 1, 2 and 3 
 
First contact mania  Chronic patients        Healthy controls 
 First 
manic 
episode 
(FM) 
Previous 
manic 
episodes 
(PM) 
Bipolar 
spectrum 
disorders 
Schizophrenia 
spectrum 
disorders 
HC 
Paper 1 
HC 
Paper 2 & 3 
Age,    
mean (SD) 
31.2 (9.6) 30.5 (10.6) 37.1 (12.6) 31.3 (9.4) 32.0 (9.2) 31.1 (9.8) 
 
Sex,  n      
male/female 
15/19 8/13 45/55 52/48 52/48 49/61 
 
Years of 
education 
mean (SD) 
13.1 (2.2) 12.9 (2.3) 13.6 (2.4) 12.1 (2.3) 14.1 (2.1) 13.4 (1.9) 
 
WASI full-
scale IQ, 
mean (SD) 
108.6 
(14.7) 
106.9 (9.6) 106.5 
(11.1) 
96.6 (16.1) 114.4 (9.6) 111.6 (11.4) 
 
PANSS-P, 
mean (SD) 
11.6 (5.5) 11.5 (3.8) 10.0 (3.5) 15.9 (5.3) -- -- 
PANSS-N, 
mean (SD) 
9.6 (3.0) 9.7 (3.8) 10.2 (4.0) 16.1 (6.8) -- -- 
GAF-F, 
mean (SD) 
54.5 (15.3) 50.1(11.0) 54.7 (11.5) 42.4 (10.7) -- -- 
GAF-S, 
mean (SD) 
47.7 (11.2) 48.9 (11.2)  57.1 (11.1) 41.2 (10.3) -- -- 
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In paper 1 two diagnostic groups were defined. The bipolar spectrum disorder group 
consisted of BD type I (62%), BD type II (30%) and BD not otherwise specified (6%). The 
schizophrenia spectrum group consisted of schizophrenia (74%), schizoaffective disorder 
(12%) and schizophreniform disorder (16%). 
The samples in paper 2 and 3 consisted of a total of 55 BD participants with a first contact 
manic episode. Patients were defined as first episode BD if they met the diagnostic criteria 
for DSM-IV BD I disorder and were receiving their first adequate treatment for a manic or 
mixed episode. Patients could have experienced previously untreated manic episodes, or 
have received treatment for a major depressive episode and still be included in the study. 
Since acutely manic patients are not always able to give informed consent, patients 
identified as first contact mania were included up to one year after start of first treatment. 
The cohort was divided into two groups according to their number of previous manic 
episodes. The first group; First Manic episode (FM; n=34), had only had one single manic 
episode lifetime (the current). The second group; Previous Manic episodes (PM; n=21), had 
experienced previous manic episodes although those episodes had neither been identified 
as manic episodes at the time, nor being adequately treated as such. 
Exclusion criteria for all participants were: history of head injury with neurological 
complications, neurological disorder, unstable medical condition that interferes with brain 
function, mental retardation (IQ < 70) and being unable to comprehend the Norwegian 
language at an acceptable level. In paper 2 and 3 participants needed to have Norwegian as 
their first language or having received their compulsory schooling in Norway, and had to 
score 15 or above on the forced recognition trial in the California Verbal Learning Test (CVLT-
II) (Delis et al., 2004). In order to assure a healthy control sample the control participants in 
all three studies were screened with the Primary Care Evaluation of Mental Disorders 
(PRIME-MD; Spitzer et al., 1999) and were excluded if they or any close relatives had a 
lifetime history of a severe psychiatric disorder (schizophrenia, bipolar disorder or major 
depression), or if they had substance abuse or dependency the last 6 months.  
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3.3. Measures 
3.3.1. Clinical assessment  
Diagnosis was based on the Structured Clinical Interview (SCID) for DSM-IV, modules A-E 
(First et al., 1995). All interviewers were trained based on the training program at UCLA (CA, 
USA), were given regular individual supervision of assessments by senior research personnel 
and participated in regular diagnosis consensus meetings. Diagnosis reliability was found 
satisfactory with agreement for DSM-IV diagnostic categories with an overall kappa score of 
0.77 (95% CI: 0.60-0.94)1. 
The level of current symptomatology was defined based on the following scales: Current 
depressive symptoms were rated using the Inventory of Depressive Symptoms-Clinician 
rating (IDS-C) (Rush et al., 1986). Current manic symptoms were rated using the Young 
Mania Rating Scale (YMRS) (Young et al.,1978). Current positive and negative symptoms 
were rated using the Positive And Negative Syndrome Scale (PANSS) (Kay et al., 1987). Inter-
rater reliability for the PANSS was acceptable with intraclass correlation coefficients (ICC) of 
0.73 (95% CI: 0.54-0.90). 
Current overall degree of present symptoms was assessed with the split version of the 
Global Assessment of Functioning – symptom level (GAF-S; Pedersen et al., 2007).  The split 
version of the GAF separates symptom and function into two different scores, the GAF-
Symptom level and the GAF-Function level (GAF-F). Here, GAF-S represents overall degree of 
symptoms. GAF-F, global clinician-rated social functioning, will be discussed in further detail 
in the next section. Inter-rater reliability for GAF-F and S was satisfactory, with an ICC of 0.86 
(95% CI: 0.77-0.92). 
Data on age, gender, ethnicity, marital status, education, occupational status, family history 
of psychiatric disorders including substance abuse, history of suicide attempts, history of 
psychosis, psychiatric hospitalizations and psychopharmacological treatment, age at onset of 
                                                          
1 The following reliability ratings apply for the total clinical sample used in paper 1, and partially the clinical 
sample used in paper 2 and 3. 
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affective episodes and age at first contact with specialized psychiatric care were also 
collected. The information was confirmed using medical charts and interviews with close 
family members if relevant. 
Patients were considered to have had a lifetime psychotic episode if they had one or more 
SCID-verified psychotic episode. Current psychosis was defined as a score of 4 or higher on 
any of the following PANSS items: P1, P3, P5, P6 and G9. 
Each patient reported lifetime substance use (daily, weekly, monthly or occasional/no use) 
for all substances including alcohol, amphetamine, cocaine, cannabis, ecstasy, heroin/ other 
opiates, hallucinogens, solvents and prescription drugs for the following life periods: 11-15 
years, 16-20 years, 21-27 years, 28-44 years, 45-60 years and 60+ years. The lifetime 
substance use evaluation is administered as an interview, where the scores are based on the 
clinician’s evaluation of the patients’ reports.  
 
3.3.2. Assessment of current and premorbid social functioning 
Social functioning was assessed with a self-rating scale and a clinician-rating scale. The Social 
Functioning Scale (SFS; Birchwood et al., 1990) was developed to measure different areas of 
functioning that are crucial to the community living of individuals with schizophrenia. The 
scale was designed with two requirements in mind: (1) to provide a detailed assessment of 
patients’ strengths and weaknesses, both to guide an intervention and to provide the 
clinician with possible specific goals, and (2) the ability to synthesize such detailed reporting 
into coherent, reliable scales (Birchwood et al., 1990). The Norwegian version of the SFS was 
translated in 2003 by members of the TOP study group; Anja Vaskinn and Kjetil Sundet, and 
back-translated to English by a bilingual research fellow; Torill Ueland. It has been accepted 
as the official Norwegian version by the British developers (PROQOLID, 2007). The 
Norwegian version of the SFS has been used in several projects (Simonsen, Sundet, Vaskinn 
et al., 2010; Vaskinn, Sundet, Friis et al., 2008a, 2008b; Øie, Sundet & Ueland, 2011). The SFS 
is constructed to measure social skills and performance among patients with schizophrenia, 
and is a self-administered questionnaire consisting of 76 items sorted into seven subscales as 
the sum of all items within each area. Each subscale is standardized and normalized to a 
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scaled score (SS) with a mean of 100 and a standard deviation of 15, based on a sample of 
334 outpatients with schizophrenia (Birchwood et al., 1990). The SFS total score is calculated 
by adding all seven subscale SSs and dividing the sum on the number of subscales (=7). The 
SFS enumerates key skills and social behaviors which informants record as present or absent. 
Items are rated on a four-point scale of frequency or ability; with a higher score indicating a 
higher frequency or more competent behavior. The SFS also distinguishes lack of 
competence from lack of performance: lack of competence refers to the absence or loss of a 
skill, while lack of performance refers to non-use of an available skill. The seven subscales 
are: 
(1) Withdrawal (time spent alone, initiation of conversation, social avoidance) 
(2) Interpersonal behavior (number of friends, having a romantic partner, quality of 
communication) 
(3) Pro-social activities (engagement in a range of common social activities, e.g. going to the 
cinema) 
(4) Recreation (engagement in a range of common hobbies and interests) 
(5) Independence-competence (the ability to perform skills necessary for independent living, 
like shopping for groceries, doing laundry etc.) 
(6) Independence-performance (the actual performance of those same skills) 
(7) Employment (engagement in productive employment or a structured program of daily 
activity) 
 
 
The GAF-Function level scale (GAF-F; Pedersen et al., 2007) was used to measure clinician-
rated social functioning. GAF is a clinician-rated scale with scores based on all available 
information. The original GAF scale is a further development of the Global Assessment Scale 
(GAS; Endicott et al., 1976) and was introduced as the axis V of the DSM-III-R in 1987. One of 
the benefits with the GAF scale is that it is not disorder-specific, but can be used across a 
wide range of mental disorders. Both GAF-F and GAF-S scales are rated from 1 to 100 with 
100 representing the hypothetically best possible functioning and 1 representing the 
hypothetically lowest possible functioning. For the purpose of study 1 and 3 only the 
function part of the scale (GAF-F) was used as a measure of social functioning. 
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To measure premorbid social functioning the Premorbid Adjustment Scale (PAS) was used 
(Cannon-Spoor et al. 1982). The PAS is a rating scale designed to evaluate the level of 
functioning in four major areas at each of several periods of the subject’s life: (1) social 
accessibility - isolation, (2) peer relationships, (3) ability to function outside the nuclear 
family, and (4) capacity to form intimate socio-sexual ties. Items evaluating age-appropriate 
functioning in these areas are repeated for each period of the subject’s life. The four period 
sections are: Childhood, up to 11 years; Early Adolescence, 12-15 years, Late Adolescence, 
16-18 years; and Adulthood, 19 years and beyond. Scores range from 0-6 where 0 represents 
the best possible functioning. The PAS was administered as part of the clinical assessment 
and was based on patients self-report. In the analyses, PAS scores were divided into two 
domains – Academic and Social – and for each domain we discriminated between level and 
change (Larsen et al. 2004). To measure initial level, we used the childhood scores for each 
domain, while change was calculated as the difference between the latest avilable score and 
the childhood level score. 
 
 
3.3.3. Neurocognitive assessment 
Neurocognitive assessment was carried out by psychologists trained in standardized 
neuropsychological testing. A three hour test battery was administered in a fixed order with 
two breaks in between. Test scores were initially calibrated across investigators in order to 
assure a common scoring technique. Measures included in this study are previously found 
sensitive to dysfunction in schizophrenia and bipolar spectrum disorders (Simonsen et al., 
2008). Although assigning tests to one specific cognitive domain remains controversial, we 
assigned the tests to the following and more specific neurocognitive functions or domains: 
 
Learning and memory 
Using the Logical Memory test, part of the Wechsler Memory Scale (WMS-III) (Wechsler, 
2007a), the total number of items immediately recalled from two short stories that each 
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were read once was used as a measure of verbal learning, while the total number of items 
freely recalled after 30 minutes was used to measure delayed verbal recall.  
From the California Verbal Learning Task (CVLT-II) (Delis et al., 2004) we used the total 
number of words repeated immediately after five reading trials of a list of 16 words as a 
measure of verbal learning. The number of words freely recalled after 30 minutes was used 
to measure delayed verbal recall.  
To assess visual memory we used the Rey-Osterrieth Complex figure test (Meyers & Meyers, 
1995). Subjects were first asked to copy a complex figure onto a sheet of paper, and after a 
30-minute time delay they were asked to draw the same figure from memory. Number of 
points earned was used to measure delayed visual recall. 
 
Psychomotor speed 
Grooved Pegboard (Klove, 1963) was used to assess fine motor speed. The task consists of a 
small board containing a set of 5x5 slotted holes angled in different directions, and small 
pegs that fits into the holes. Each peg has a ridge along one side, requiring it to be rotated 
into position for correct insertion. The subject is asked to fill pegs in all holes, and the score 
is time to completion. We used an average of right and left hand to calculate scores. 
To assess psychomotor speed Digit Symbol-Coding, a part of the Wechsler Adult Intelligence 
Scale (WAIS-III) (Wechsler, 2003), was used. The test consists of a printed sheet with rows 
containing small blank squares each paired with a randomly assigned number from one to 
nine. Above these rows are a printed key that pairs each number with a different nonsense 
symbol. The subject must fill in the blank spaces with the symbol that is paired to the 
number above for 120 seconds. Number of spaced filled out correctly was used to measure 
psychomotor speed. 
From the first trial in the Color-Word Interference Test, part of the Delis Kaplan Executive 
Functioning Scale (D-KEFS)  (Delis et al., 2005), the color naming task was the time taken to 
name the color of different ink dots on a paper, and the second task, word reading, 
consisted of time taken to read words on a paper.  
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Attention  
Attention was assessed using the Digit Span from the Wechsler Adult Intelligence Scale 
(WAIS-III) (Wechsler, 2003). The maximum number of digits repeated in the same order as 
presented (forward version) was used as a measure of focused attention and the maximum 
number of digits repeated in a backward order of appearance (backward version) was used 
as a measure of working memory. 
In Letter-Number sequencing, also from WAIS-III, subjects hear lists of randomized numbers 
and letters of increasing lengths, and are asked to repeat numbers and letters from the 
lowest in each series, and numbers always first. 
The Bergen n-back Test (N-back) (Haatveit et al., 2010) is a computer-based test requiring 
subjects to press a button every time two numbers displayed on the screen are the same as 
the numbers displayed two screen pictures back (‘2-back’). The d’ is calculated from hit-rate 
and false alarm rate using the formula d’ = ZHIT – ZFA where Z represents a transformation of 
the two distributions allowing for comparison of measures with different ranges of absolute 
values. 
 
Executive function 
Executive function was assessed using subtests from the D-KEFS battery (Delis et al., 2005). 
From the Verbal Fluency subtest, the number of words beginning with the letters ‘F’, ‘A’ and 
‘S’ generated separately within 60 seconds was used as a measure of phonetic fluency. The 
number of animals’ and boys’ names generated separately within 60 seconds was used as a 
measure of semantic fluency. Finally, the number of fruit and furniture generated while 
alternating between the two categories was used as a measure of semantic set-shift.  
From the third trial in the Color-Word Interference Test, also part of the D-KEFS (Delis et al., 
2005), the time taken to name the color of the ink on a list of written names of colors that 
are incongruent with the color of the ink was used to measure interference control. From 
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the fourth trial, the time taken to complete the alternation between naming the color of the 
ink and naming the written word was included as a measure of interference set shift. 
The Wisconsin Card Sorting Test (Kongs et al., 2000) is a computer-based task where the 
subject is asked to place cards with four different printed symbols – triangle, star, cross or 
circle – in red, green, yellow or blue, one by one under four stimulus cards on the screen. 
After each response the person will get a feedback on the screen whether the response was 
correct or not. The placement will be correct for a nontarget category as well as a target 
category such as matching both color and form. Perseverative responses occur when the 
subject continues to sort according to a previously successful principle or persists in sorting 
on the basis of an initial erroneous guess. Categories achieved refer to the number of correct 
runs of ten sorts.  
 
IQ 
Premorbid IQ was measured using the National Adult Reading Test (Nelson & Willison, 
1991), Norwegian version (Sundet & Vaskinn, 2008).  
The Wechsler Abbreviated Scale of Intelligence (WASI) (Wechsler et al., 2007b) consists of 
four tests; Vocabulary, Similarities, Block Design and Matrix Reasoning. On the Vocabulary 
task subjects are asked to explain the meaning of different words, in order of difficulty. In 
Similarities the subject must explain what each of a pair of words has in common. Block 
Design is a construction test where subjects are presented with red and white blocks and the 
task is to use the blocks to construct replicas of designs of increasing difficulty printed in a 
scale smaller than the blocks. In Matrix Reasoning the subject must choose from a multiple-
choice array of visual patterns the item that best completes the pattern.  
 
Clinically significant cognitive impairment 
Neurocognitive dysfunction was investigated by comparing the mean performance for the 
different groups, however we were also interested in how many of the patients were 
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impaired to a degree that would be considered clinically significant. To assess cognitive 
impairment, the proportion of BD- and healthy control participants with clinically significant 
cognitive impairment, defined as neurocognitive scores 1.5 SD below the average of the 
healthy control group was calculated. Accordingly, the cut-off of 1.5 SD would also define 7% 
of the healthy control participants as impaired as it captures participants performing below 
the normative seventh percentile level. 
  
 
3.4. Statistical analyses 
All analyses were performed using the Statistical Package for the Social Sciences (SPSS Inc., 
Chicago, IL, USA) version 16.0. Group comparisons of demographics, clinical characteristics, 
neurocognition and social functioning were carried out with a range of analyses. Group 
differences across continuous variables were investigated with t-tests, Mann-Whitney U 
tests or analyses of variance (ANOVA), while categorical variables were investigated with 
Chi-square analysis. Correlations between variables were explored by Spearman or Pearson 
rank correlations according to type of data. All tests were 2-tailed, and limits for significance 
was set to the 0.05- or 0.01 level, the latter due to multiple comparisons. 
Reliability analyses in paper 1 was performed by reporting mean item-total correlations, 
mean inter-item correlations, and Chronbach’s alpha for the seven subscale scores and full 
scale score. Pearson’s product-moment correlations (r) between both the SFS full scale score 
and the seven subscale scores, and between the seven subscale scores was reported. 
Principal component analysis (with Varimax rotation when more than one component was 
indicated by Eigenvalues > 1.0), was performed using the seven subscale scores, both for the 
total sample as well as within the SZ, BD and HC groups separately.  
Effect sizes were reported by the squared eta-correlation (n2) in all three papers, in addition 
to z-scores that were used in paper 2. 
In paper 2, group differences of neuropsychological test performance was explored using 
between-subjects univariate ANOVA with effect size (eta squared) of group differences and 
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Scheffès post hoc tests. Bonferroni corrections were applied for all cognitive domains. 
Analysis of covariance (MANCOVAs) investigated if group differences in neurocognitive 
performance remained significant when psychomotor speed was controlled for by entering 
Digit Symbol Coding as covariate.  
In paper 3, hierarchical multiple linear regression analyses with variables entered in blocks 
was carried out to explore the independent contribution of neurocognition and current 
symptomatology to self-rated (SFS) and clinician-rated (GAF-F) psychosocial function. We 
chose clinical and neurocognitive variables that correlated > .20 with at least one of the 
functional measures in the bivariate analyses for the regression analyses. In the analyses 
clinical and premorbid variables were entered in block 1 and neurocognitive measures in 
block 2.  
A thorough description of the statistical analyses used in the three studies, are given in the 
three papers. 
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4. SUMMARY OF PAPERS 
 
Paper I: Validation of the Norwegian version of the Social Functioning Scale (SFS) for 
schizophrenia and bipolar disorder 
Background: Studies of social functioning in severe mental disorders have been challenged 
by the multitude of different assessment instruments in use. The present study aims to 
establish reliability and validity of the Norwegian version of the Social Functioning Scale (SFS) 
and to examine social functioning in bipolar disorder (BD) compared to schizophrenia (SZ) 
and healthy controls (HC). 
Methods: SFS, a 76 item questionnaire divided into seven subscales measuring various 
aspects of daily life functioning, was administered to samples diagnosed with BD (n = 100) or 
SZ (n = 100) and to HC subjects (n = 100), recruited from the ongoing Thematic Organized 
Psychosis research (TOP) study. 
Results: Reliability analyses based on the three groups combined (n= 300) prove adequate 
psychometric properties both for the composite full scale score (alpha: 0.81) as well as for 
the seven subscale scores (alpha: 0.60-0.88). Principal component analysis of the subscale 
confirms a one-component structure, explaining 59% of the variance. Looking at the groups 
separately, a one-component solution was preferred for the BD group, while a two-
component solution for the SZ group, and a three-component solution for the HC group was 
suggested. 
Conclusion: Although significantly correlated with the Global Assessment of Functioning, our 
results indicate that the SFS measures different aspects of social functioning, is less 
influenced by demographic and clinical characteristics, but differentiates at the same time 
significantly patients with severe mental illness from healthy controls. The scale seems to 
work well for patients with BD. Thus, SFS adds valuable information as a supplement to 
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standard clinician-rated assessment tools of social functioning, suited for both research and 
clinical work. 
 
 
Paper II: Neurocognitive functioning in patients recently diagnosed with bipolar disorder 
 
Background: Cognitive dysfunction in bipolar disorder is well established in the literature; 
however, there are few studies of neurocognition in patients early in the course of the 
illness. In the present report, we describe neurocognitive function in a first contact mania 
sample – separated into two groups based on the number of previous untreated manic 
episodes – compared to an age, gender and education matched sample of healthy control 
participants. A particular emphasis will be laid on the deficits and proportion of clinically 
impaired participants.  
Methods: Patients with first episode mania (FM, n= 34) or previous untreated mania (PM, n= 
21) were neuropsychologically tested after their first treated manic episode, along with 110 
matched healthy control comparison subjects. The cognitive domains evaluated included 
verbal- and visual learning and memory, attention, processing speed, executive functioning 
and IQ. Results were corrected for speed of processing differences, and compared to clinical 
symptoms as well as previously reported results for multiepisode bipolar disorder patients. 
Results: Patient groups showed impairments in psychomotor speed, attention, learning and 
memory, executive functioning and IQ. No significant differences in neurocognition were 
found between the two patient groups. When controlling for psychomotor speed, measures 
of visuoconstructive reasoning and motor dexterity remained statistical significance. The 
mean proportion of patients with clinically significant impairment was 18% for FM and 16% 
for PM. There were no significant relation between clinical symptoms and neurocognition, 
but indications of smaller deficits compared to multiepisode patients. 
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Conclusion: Neurocognitive dysfunctions are present early in the course of bipolar disorder 
and reaches the level of clinical significance for a subgroup of individuals. Comparing the 
results to neurocognitive findings in a non-overlapping sample of multiple-episode BD 
patients from the TOP study group, our findings also suggest that the neurocognitive 
dysfunction may increase with illness progression. 
 
 
Paper III: Social functioning in first contact mania – clinical and neurocognitive correlates 
 
Background: Social dysfunction occurs in more than half of all patients with bipolar disorder 
and is likely to be present early in the illness course. In the current report from the Thematic 
Organized Psychosis (TOP) study we aimed study the association between social functioning 
and neurocognition in a sample of first-episode bipolar disorder patients using both self- and 
clinician-rated instruments. 
Methods: Patients with a first manic episode (FM, n= 34) or previous manic episodes (PM, n= 
21) and 110 healthy control subjects (same sample as in paper II) matched for age, sex and 
education completed a self-report assessment form of social functioning, the Social 
Functioning Scale (SFS). Patients’ level of functioning was rated by a clinician using the split 
Global Assessment of Functioning – Function scale (GAF-F), and the patients also underwent 
neuropsychological testing. 
Results: Both patient groups had significantly lower self-rated social functioning compared to 
healthy controls on all subscales and total score of the SFS. Patients with previous untreated 
manic episodes tended to rate their functioning as more impaired than patients with a first 
manic episode. In multivariate analysis exploring the relationship to clinical symptoms and 
neurocognition, current depressive symptoms and processing speed had an independent 
contribution to self-rated social functioning, and psychotic symptoms to clinician-rated social 
functioning. 
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Conclusion: Impairment of social functioning in bipolar disorder is present already after a 
first manic episode, and is associated with a number of clinical variables although depressive 
symptoms had the strongest influence on self-rated social functioning. Neurocognition, 
except from processing speed, did not appear to have a significant influence on social 
functioning at this stage of the illness. Patterns of association were different for self-rated 
compared to clinician-rated functioning. 
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5. DISCUSSION 
The main findings from the three papers in this thesis are discussed in light of previous and 
later research (5.1), implications of the findings (5.2), clinical implications (5.3) and 
methodological issues (5.4). Finally, the study’s main strengths and limitations are raised 
along with suggestions for further research (6). 
 
5.1. Main findings 
5.1.1. Validation of the Norwegian version of the Social Functioning Scale (SFS) 
Because we were interested in studying social functioning in first-episode BD, there was a 
need to investigate the reliability and validity of the instrument we had chosen for the 
measurement of social functioning. We examined the psychometric properties of the scale in 
a Norwegian sample, and since the scale had originally been developed for schizophrenia 
(SZ) patients only, we investigated its usefulness for BD participants also.  
The main finding of this first paper was that SFS showed good psychometric properties also 
in its Norwegian version. The Chronbach’s alphas were calculated based on the total sample 
(n= 300), and ranged from 0.60 to 0.88 for the seven subscales, with a score of 0.81 for the 
full scale. This is comparable to the original sample (SFS total score: 0.80 [subscales range 
0.69 – 0.87]; Birchwood et al., 1990), and the translated Spanish version (SFS total score: 
0.80 [subscales range 0.69 – 0.80] Torres & Olivares, 2005), indicating that the SFS can be 
used reliably in a broad range of clinical and language settings. 
The seven subscales were found to form a single construct in accordance with previous 
reports, explaining 59% of the variance in the total sample. The component analysis supports 
the validity of calculating a single score as a measure of social functioning based on SFS 
ratings (Birchwood et al., 1990; Torres & Olivares, 2005). The one-component structure was 
maintained also for patients with BD. However, a two-component structure was suggested 
for the SZ group, with employment as a second dimension in addition to the other subscales. 
44 
 
For healthy controls, a three-component structure was suggested. A study including SZ 
patients and healthy controls, also reported a three-component structure of the seven SFS 
subscales (Pijnenborg et al., 2009). Total explained variance in their study was 70%. 
However, it was not clear if their analysis was performed on the total sample or was 
restricted to the schizophrenia group. Our findings are similar but not identical for both our 
SZ and healthy control groups, whereas our main analysis for the whole sample supports the 
validity of a single-component structure. 
The SFS was found to be a valid measure of social functioning by its significant correlations 
of the SFS Total score with the GAF-F score in both clinical groups, with medium to large size 
effects (SZ: r = 0.27, p < 0.05; BD: r = 0.46, p < 0.01). Although the sub scales measure 
specific and limited functions, thus making them less suitable for a comparison with a global 
measure like the GAF, we correlated all SFS sub scales (scaled scores) for both diagnostic 
groups with the GAF-F (data not in paper). For the SZ group, the GAF-F correlated 
significantly only with two sub scales (Withdrawal and Interpersonal behaviour), whereas 
the GAF-F correlated significantly with all sub scales except Independence – competence in 
the BD group. Correlations were also higher in the BD group than in the SZ group. This 
suggests that the patients’ self-report of social functioning share a moderate degree of the 
variance with the observed, clinician-rated functioning, and also that the SFS Total score can 
be used independently, especially for SZ patients. 
The SFS did not correlate with age, sex and IQ in either diagnostic group, and can thus be 
used without correcting for these demographic variables. Regarding clinical symptoms, when 
correlating the SFS to other measures, we found moderate but significant correlations for 
negative symptoms, depressive symptoms, GAF-S, work ability and education. On the other 
hand, the GAF-F correlated moderately but significantly also to a number of clinical 
characteristics such as depressive symptoms, work ability, educational level, social situation 
and housing. This may be seen as an indicator that the two scales measure somewhat 
different aspects of social functioning. Overall, the SFS appears to measure more diverse, 
subtle and specific aspects of social behaviors that are also more independent of clinical 
symptoms. 
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Case-wise, the instrument was shown to reliably classify participants above chance level into 
their true groups, with a particularly good discrimination between healthy controls and 
patients – 94% of healthy controls were correctly classified. The best classification was found 
for people with SZ and healthy controls; one third of BD patients rated themselves similar to 
the profile of the SZ group. Therefore, in the current study SFS did not distinguish precisely 
between BD and SZ participants. 
To investigate how sensitive the SFS total score was in assessing level of social functioning, 
we tabulated the distribution of scores for each group, using the same score ranges as in the 
original study (Birchwood et al., 1990). The HC scores clustered around a higher median than 
both SZ and BD participants. None of the individuals with SZ obtained scores within the 
highest range (126-135), compared to 9% in the BD group and 45% in the HC group. Scores 
below 115 were given to 82% of BD patients and 93% of SZ patients, while only 4% of the 
HCs rated themselves within this range. 
There were significant group differences between the SZ, BD and healthy control groups for 
all subscales and total score. On subscales 5 – independence-competence and 6 – 
independence-performance the two clinical groups did not differ significantly. On all other 
subscale scores and SFS total score, the BD group scored better than the SZ but poorer than 
healthy controls. This was in the expected direction and suggests that patients with BD 
experience social dysfunction as reported in recent studies (MacQueen et al., 2001; Sanchez-
Moreno et al., 2009). 
In conclusion, the study has provided support for the reliability and validity of the Norwegian 
version of the Social Functioning Scale. The scale can be used on patients groups with both 
SZ and BD, and discriminates well between patients and healthy controls. The scale appears 
to measure slightly different aspects of of social functioning compared to the GAF-F, and to 
be less influenced by the effect of clinical symptoms. 
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5.1.2. Neurocognitive functioning in first contact mania  
The main finding of this second paper is that neurocognitive deficits are present among BD 
patients already at the time of their first treatment for a manic episode. This applies to both 
the patient group with no previous manic episodes and to the patient group with previous 
untreated episodes. Despite differences in age at onset, number of episodes and treatment 
delay between the two patient groups, they were generally performing similarly on most 
neurocognitive measures. There were statistically significant differences between the 
patient groups and the healthy control group on measures of verbal recall, psychomotor 
speed, attention and some aspects of executive function as well as visuoconstructive 
reasoning. These results support findings from previous studies of neurocognition in first-
episode mania with more limited samples (Nehra et al., 2006; Torres et al., 2010). The 
domain with the most prominent and statistically significant differences between groups 
was psychomotor speed. Here all measures except word reading was significantly lower in 
both patient groups compared to the HC group. Impairments in processing speed in BD is 
previously documented in the literature (Robinson et al., 2006) and has also been observed 
in unaffected family members (Ferrier et al., 2004; McIntosh et al., 2005), suggesting a 
heritable component. The domains with the least significant differences between groups 
were verbal learning and memory, executive functioning and IQ.  
The groups were matched on age, gender and education, but not current or premorbid IQ. 
Of particular interest is the finding that premorbid IQ (NART) was found no different in the 
BD group compared to the HC group. We have previously reported the same pattern in BD 
groups with multiple episodes (Simonsen et al., 2008). 
The degree of cognitive impairment varied across domains. An average of 18% of the FM 
group, 16% of the PM group and 7% of the HC group were considered clinically impaired 
across cognitive measures. On the learning and memory tasks, 23% of FM and 14% of PM 
compared to 7% of the HCs had clinically significant impairment. Impairment of 
psychomotor speed was found in 21% of FM and 25% of PM participants compared to 7% of 
HC participants. For attention and working memory, and average of 13% of FM and 12% of 
PM participants were considered clinically significantly impaired, whereas 4% of HC 
participants had impairment on these tasks. Regarding executive functioning, 15% of FM, 
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11% of PM and 6% of HC participants had clinically significantly cognitive impairment. On the 
IQ measures, 17% and 19% of the FM and PM groups had impairment, compared to 8% of 
HC participants. Overall, twice as many participants from the two bipolar disorder groups 
had clinically significant cognitive impairment compared to healthy controls. 
 
Comparing the present findings to the results from our group’s previously published study of 
BD patients with multiple episodes (Simonsen et al., 2008), we found that the magnitude of 
dysfunction in first contact mania patients was comparable to multiple-episode BD patients 
on certain measures of verbal recall (CVLT-II delayed recall) and executive functioning (Color-
Word Interference test). For the remaining tasks which includes verbal learning (Logical 
Memory and CVLT-II learning), attention (Digit Span backwards, Bergen n-back) and other 
measures of executive functioning (Verbal fluency), consistently smaller cognitive deficits 
were present in first contact mania patients compared to multiple-episode BD patients. The 
consequences of this finding will be further discussed under (5.2.) Implications.  
 
Contrary to expectations there was a lack of associations between clinical variables such as 
number of manic episodes and neurocognition. We did find a trend towards a significant 
association between level of depression and a measure of executive functioning (verbal 
fluency set shifts), in a direction indicating that higher levels of depression was associated 
with a better performance. This is in contrast to most previous findings. For instance, 
increased severity of depressive symptoms in unipolar major depression has been shown to 
be significantly associated with reduced cognitive performance across episodic memory, 
executive functioning and processing speed (McDermott & Ebmeier, 2009). In BD, depressive 
symptoms have also been associated with dysfunctions in psychomotor speed, speed of 
information processing and attentional switching (van der Werf-Elderling et al., 2010). 
When correcting for psychomotor speed (Digit Symbol Coding), two neurocognitive 
measures (Grooved Pegboard and Block Design) remained statistically significant, and a third 
measure (Letter-Number Sequencing) lost its significance after Bonferroni correction. This 
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might suggest that motor speed, attentional and visuoconstructive measures are the most 
sensitive tests in this sample. 
In conclusion, we here show that neurocognitive dysfunction is present early in the course of 
BD and reaches the level of clinical significance in a subgroup of individuals. Comparing our 
results with multiple-episode patients, the findings also suggest that the neurocognitive 
dysfunction may increase with illness progression. 
 
 
5.1.3. Social functioning in first contact mania  
The main finding of this last paper was that the BD patients displayed evident signs of social 
dysfunction after their first treatment for a manic episode. Both the FM and PM groups 
scored significantly lower on all subscales of the SFS compared to healthy controls. This 
included interpersonal relationships, leisure activities, skills necessary for independent living, 
and work functioning. These findings are consistent with findings from studies of more 
chronic BD patients (Haro et al., 2010; MacQueen et al., 2001) as well as studies of patients 
early in the illness course (Kauer-Sant’Anna et al., 2009; Torres et al., 2010). Patients with 
previous manic episodes rated themselves lower than patients with a first manic episode on 
the subscales Independence-Competence, Prosocial activities and Employment – as well as 
having a significantly lower SFS Total score. 
There was no association between premorbid social functioning and current social 
functioning. The findings from our sample also show a normal functioning up until illness 
onset in both clinical groups. Cannon et al (1997) reported contrary to our results that adult-
onset BD had significantly poorer overall and adolescent premorbid adjustment than healthy 
controls and that the BD group did not differ from a schizophrenia comparison group on 
sociability. However a later study could not confirm this finding (Uzelac et al., 2006).  
When correlating the measures of self- and clinician-rated social functioning with clinical 
measures, we found a significant relationship between a number of clinical variables and 
social functioning. Regarding self-rated social functioning (SFS), cannabis use was 
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significantly negatively correlated with social functioning, indicating that patients who 
reported having used cannabis also reported poorer social functioning. Current depression 
and number of depressive episodes was also significantly negatively correlated with self-
rated social functioning, showing that the more depressive symptoms or episodes the worse 
social functioning. There was also a positive correlation between age at onset and SFS 
indicating that a better functioning was associated with a later onset of BD. The relationship 
between earlier age at onset and reduced social functioning has been reported in previous 
studies (Meeks, 1999; Perlis et al., 2009). 
Regarding the GAF-F, clinician-rated social functioning was correlated with psychotic-, 
depressive- and manic symptoms showing that a higher symptom load was associated with 
poorer clinician-rated functioning. 
The relationship between depressive- or subclinical depressive symptoms and impairment of 
social functioning have been reported in several investigations (Bonnin et al., 2010; Fagiolini 
et al., 2005; Kauer-Sant’Anna et al., 2009; Martino et al., 2009; Mur et al., 2009; Simon et al., 
2007). Manic and psychotic symptoms were associated with lower clinician-rated social 
functioning but not lower self-rated social functioning. Morriss et al (2007) reported that 
hypomanic symptoms increased friction and impaired adjustment with the extended family, 
and Judd et al (2005) reported a stepwise progression in disability associated with each 
increment in manic or hypomanic symptom severity in BD I. Although we did not investigate 
use of other illegal substances than cannabis, previous studies have reported that substance 
use disorders (Mazza et al., 2009; Weiss et al., 2005) or excessive substance use including 
cannabis (Lagerberg et al., 2010b) are associated with poorer social functioning. 
 
There were no significant correlations between neurocognition and self- or clinician-rated 
social functioning. This is in contrast to other findings (Altshuler et al., 2008; Bonnin et al., 
2010; Martinez-Aran et al., 2007; Martino et al., 2009; Mur et al., 2009), including a study on 
non-first episode BD from our own TOP study group, that reported both self-rated (SFS Total 
score) and clinician-rated (GAF-F) social functioning correlating significantly with five 
neuropsychological measures and symptom ratings (Simonsen et al., 2010). However 
findings from another study of a first-episode BD group are in line with our results. Here 
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Torres (Torres et al., 2010) reported an association between baseline neurocognition and 6-
month functional outcome, however they failed to find an association between baseline 
cognition and concurrent baseline psychosocial functioning in newly diagnosed BD patients.  
 
Results from the multiple regression analysis show that both depressive symptoms and 
surprisingly, good processing speed, had an independent contribution to self-rated social 
functioning. The latter is rather contrary to expectations, but it is possible that individuals 
with a better cognitive functioning are more aware of their social difficulties, or have a 
higher standard of what they think they should be able to manage. Only psychotic symptoms 
significantly influenced clinician-rated social functioning.  
 
In conclusion, impairment of social functioning in BD is present already after a first manic 
episode. Patients with more previous mood episodes and longer treatment delay reported 
more social impairment and were less likely to be engaged in full-time employment or 
studies. The main predictors for both self-rated and clinician-rated social functioning are 
clinical symptoms, with depression associated with self-rated function and psychotic 
symptoms with clinician-rated function. Processing speed had a significant influence on 
social functioning, while other neurocognitive measures did not appear to play a significant 
role in social functioning at this stage of the disorder.  
 
 
 
5.2. Implications 
5.2.1. Evidence for accelerated cognitive decline? 
As previously mentioned, there were clear signs of neurocognitive deficits in patients with 
BD already after treatment of a first manic episode. Psychomotor speed was the most 
impaired cognitive domain in both BD groups compared to the HC group, but the patients 
also had significant impairment on measures of attention, verbal recall, executive 
functioning and visuoconstructive reasoning, consistent with findings from previous meta-
studies of neurocognitive impairment in BD (Bora et al., 2009; Kurtz & Gerraty, 2009; 
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Robinson et al., 2006; Torres et al., 2007). Comparing the results to a non-overlapping 
sample of multiple-episode BD patients (Simonsen et al., 2008) provides a preliminary 
framework for determination of the longitudinal course of cognitive impairment of the 
illness.  
 
 
Figure 1: Patient-control performance in First contact mania (FM and PM groups 
combined) and Multiple treated episodes BD 
 
 
 
 
 
 
 
 
 
 
 
 
The figure shows that the magnitude of dysfunction in the total first contact mania sample is 
comparable to the multiple-episode sample on verbal recall and some aspects of executive 
functioning. For the remaining tasks, consistently smaller deficits are present in the first-
episode BD group. This might suggest that cognitive impairment in certain domains may 
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progress with advancing illness course, while others may already be impaired at illness 
onset. However as this is a comparison of cross-sectional data, it is possible that the 
differences in magnitude of cognitive impairment are related to characteristics of the 
samples, particularly the multiple-episode group. For instance, the persons in the multiple-
episode sample might represent a subgroup with a more adverse illness course and more 
cognitive dysfunction, which makes them remain in the specialized health-care system over 
several years.  
Torres and colleagues (2010) compared findings from their sample of first-episode BD 
patients to previously published meta-analytic data of multiple-episode patients and found 
comparable cognitive deficits on tasks of premorbid/verbal intellectual ability and 
attention/processing speed, while deficits in executive functioning and verbal memory were 
consistently smaller in the first-episode patients. Although the findings differed somewhat 
from our results, they too suggest that cognitive impairment in certain domains may 
progress somewhat over the course of BD.  
Cognitive functioning have been negatively related to number of episodes, number of 
hospital admissions and duration of illness (Robinson & Ferrier, 2006), but this could also be 
interpreted as patients with greater cognitive impairment being less able to manage their 
illness with a poorer illness course as a result. A 2-year longitudinal study of euthymic BD 
outpatients showed that impairment in executive function and processing speed was 
maintained over the time period, and these deficits seemed to be persistent but stable over 
time (Mur et al., 2008). However, the patient sample had an average duration of illness of 17 
years at entry of the study, which might explain why no decline in any cognitive functions 
during that period was found. Alternatively, cognitive impairment may manifest in early life, 
but significant decline may not be apparent until late middle or older age. Gildengers et al. 
(2009) investigated longitudinal cognitive functioning in older persons with BD, and found 
that they presented with more cognitive dysfunction and more rapid cognitive decline than 
expected given their age and education. The evidence for an accelerated cognitive decline in 
BD is still preliminary and neurodegeneration may or may not be the correct term for the 
harmful effects of repeated episodes and neurotrophic medications on cognitive 
performance (Goodwin et al., 2008). More longitudinal studies, preferably on first-episode 
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patients are needed to explore the relationship between illness course and cognitive 
impairment. 
 
5.2.2. Neurocognitive impairment independent of clinical course and social dysfunction? 
Apart from a trend towards a significant association between level of depression and a 
measure of executive functioning, we did not find any significant relationship between 
neurocognitive impairment and clinical characteristics such as manic or psychotic symptoms, 
or the number of episodes. This is in contrast to previous research (el-Badri et al., 2001; 
Robinson & Ferrier, 2006), and it also questions the strong association between illness 
progression in the form of manic episodes and neurocognition suggested by previous studies 
(Lopez-Jaramillo, 2010). Some areas of neurocognitive functioning have been suggested as 
illness traits rather than state variables. For instance, sustained attention deficits has been 
demonstrated in euthymic BD patients, and there are preliminary indications that this deficit 
is present from the first episode, but also becomes more severe with the progression of the 
disorder (Clark & Goodwin, 2004). Impairments in verbal learning and memory have also 
been found to be persistent during the euthymic phase of BD and may represent trait 
variables, but are also related to the number of affective episodes (Cavanagh et al., 2002). 
Impulsivity in BD has also been suggested having both affective state-dependent and trait 
components (Strakowski et al., 2010). This profile of trait impairment combined with state 
modulation is interesting because it provides a link between etiological factors and the 
processes that trigger and exacerbate symptoms during acute episodes. Our neurocognitive 
results thus seem to be independent of the clinical course at this specific stage of the illness, 
and might therefore represent trait variables. Alternatively, the lack of findings might be 
based on lack of statistical strength, since the design of the study necessary set restrictions 
on the number of previous mood episodes, especially elevated mood episodes.  
Contrary to previous findings (Wingo et al., 2009) there was no significant correlations 
between neurocognitive functioning and self- or clinician-rated social functioning. However, 
the findings are in line with an equivalent study of first-episode BD patients that also failed 
to find an association between baseline neurocognition and social functioning (Torres et al., 
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2011). It is possible that baseline ratings may have overestimated disability or the relatively 
high level of depressive symptoms might have disturbed the relationship thus compromising 
the power to detect expected associations. The multiple regression analysis revealed a 
significant relationship between Digit Symbol, a measure of processing speed, and self-rated 
social functioning. Processing speed have been related to impaired social functioning in 
other studies (Mur et al., 2008; Tabares-Seisdedos et al., 2008), and one study of BD patients 
followed up 15 years after an index manic episode found that Digit Symbol was the sole 
predictor of social functioning in that sample (Burdick et al., 2010). However, the direction of 
both non-significant correlations and multiple regression in our findings were rather 
unexpected, suggesting that patients with a good cognitive functioning rated themselves as 
having a poorer social functioning. A possible explanation might be that individuals with a 
better cognitive functioning are more aware of their difficulties related to for instance 
relationships, work and self-care, or they might be more likely to compare themselves to 
peers or have a higher expectation of what they think they should be able to manage. Bowie 
and colleagues (2007) have also reported better cognitive skills among schizophrenia 
patients who underestimated their everyday real-world performance. Similarly, individuals 
with poor cognitive functioning might be less aware of their social difficulties, which could 
be related to insight. In a report from the TOP study group, Engh and colleagues (2011) 
demonstrated that overconfidence in own beliefs was associated with cognitive dysfunction 
in schizophrenia. Working memory deficits have also been related to poorer general insight 
in bipolar disorder (Varga et al., 2007).  
 
5.2.3. Premorbid and current social functioning in first contact mania 
Both the FM and PM groups’ premorbid self-reported social functioning was good up until 
illness onset. Not many studies have investigated this previous to the current study, and 
results have been conflicting (Cannon et al., 1997; Uzelac et al., 2006). The finding that 
premorbid functioning was not impaired in the first contact mania patients is in contrast to 
findings from studies of patients with schizophrenia (Norman et al., 2005; Saracco-Alvarez et 
al., 2009.) Findings from first-episode psychosis patients has found impairment in premorbid 
functioning (Monte et al., 2008) and even young people at clinical high risk for psychosis 
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have demonstrated significant deficits in social functioning at the pre-psychotic phase of the 
illness (Addington et al., 2008). Accordingly, the findings from our study suggest that 
impairment in social functioning is related to the onset of BD.  
Regarding current social functioning, both FM and PM group members rated themselves as 
lower functioning on all SFS subscales compared to the HC group. They were also evaluated 
as moderately impaired by the research fellow. These findings show that patients with BD 
have substantial functional impairment early in the course of the illness.  A number of 
clinical characteristics were related to level of functioning among the patients with first-
episode mania. Depressive symptoms correlated significantly with both self- and clinician 
rated social functioning. Cannabis use, age at onset and number of depressive episodes was 
significantly associated with self-rated social functioning, while current positive psychotic- 
and manic symptoms was significantly related to clinician-rated social functioning. Taken 
together, the findings from premorbid- and current social functioning suggests that 
impairments in functioning are related mainly to illness onset and the clinical symptoms 
associated with having BD. This differentiates BD from schizophrenia regarding functioning, 
as premorbid functional impairment is believed to be present before illness onset in 
schizophrenia. 
 
 
5.3. Clinical implications 
 
5.3.1. The impact of cognitive impairment 
About 1/6 of the first contact mania cohort had clinically significant neurocognitive 
impairment – meaning that impairment would be so severe that it would be expected to 
interfere with everyday life. Results from multiple-episode BD patients from the same 
catchment area showed that 1/4 of the group had clinically significant cognitive impairment 
(Simonsen et al., 2009).  
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The clinical impression of patients with BD as a group is often a relatively heterogeneous 
one. Many patients seems to have satisfactory functioning between episodes, a more benign 
course of illness and little psychiatric comorbidity, while others have a worse illness course 
and poorer functioning between episodes. The same could perhaps be the case for cognitive 
functioning, as a subgroup of patients with BD experience clinically significant cognitive 
impairment that is likely to interfere with their functioning at work, school or other activities 
of daily life. However, the majority of BD patients do not have clinically significant cognitive 
impairment. Still, cognitive impairment causes subjective distress among many patients with 
BD, and is related to poor treatment adherence in BD patients, although the causal 
relationship is uncertain (Martinez-Aran et al., 2009). Regarding possible interventions 
specifically targeting cognitive dysfunction, cognitive remediation have traditionally received 
much more investigation in the schizophrenia field, but later research shows promising 
results for patients with BD as well (Deckersbach et al., 2010). These findings underline the 
importance of assessing neurocognitive functioning in patients with BD, and suggest that at 
least a subgroup of patients are in need of treatment aimed at enhancing cognitive 
functioning. 
 
5.3.2. Group differences between patients with a first manic episode and patients with 
previously untreated manic episodes 
The FM and PM groups differed on a number of important clinical characteristics. The PM 
group had a longer treatment delay, an earlier age at onset, and more previous mood 
episodes of both polarities as well as more psychotic episodes. Accordingly, the group 
differences found in social functioning may not necessarily relate to the number of manic 
episodes per se. Patients in the PM group tended to rate themselves as less competent in 
performing skills necessary for independent living and participated less in social activities 
than FM group members.  They were also less likely to be engaged in full-time employment, 
due to being on a medical leave, which possibly is a consequence of a more severe illness 
course.  
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 Number of previous episodes (MacQueen et al., 2000) and an earlier age at onset of BD 
(Perlis et al., 2009) has previously been associated with a poorer functioning in BD. We did in 
fact find that lower self-rated social functioning was significantly correlated with both earlier 
age at onset and more depressive episodes. Interestingly, no differences in clinician-rated 
functioning were found between the groups. It could be that people who have suffered from 
the illness for a while, lose confidence in their own ability to function. Another possibility 
might be that being left out of a productive work setting also limits other areas of 
functioning – for instance having a smaller social network or not having financial means to 
participate in certain activities like visits to a restaurant or theater.  
 
5.3.3. The impact of depressive symptoms on social functioning 
Impaired social functioning was related to current depression and number of depressive 
episodes. On average both patient groups were mildly depressed. It has previously been 
found that BD I patients primarily have a depressive rather than manic symptomatic 
structure, and subsyndromal and minor affective symptoms predominate the illness course 
(Judd et al., 2002). The presence of residual symptoms at remission from depression appears 
to have long-term clinical significance. Longitudinal studies of patients with subclinical 
depression after a major depressive episode has found that they experience more 
depressive symptoms and minor depression over time (Judd et al., 2000; Kennedy et al., 
2004) and showed greater impairment in longitudinal social adjustment (Kennedy et al., 
2004). Depressive symptoms also play a major role in the quality of life (QoL) in patients with 
BD (Brissos et al., 2008). Even minor depressive symptoms have been associated with 
reduced QoL (Nierenberg et al., 2010). Full functional recovery after an episode of 
depression should therefore be the goal of treatment as enduring residual symptoms lead to 
long-term psychosocial impairment (Kennedy et al., 2007).  
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5.3.4. The use of the SFS as a self-rating scale for social functioning in BD 
The findings of this thesis suggest that the Social Functioning Scale is a reliable and valid self-
rating instrument for patients with BD. The scale is easy to administer and provides 
information of the individuals’ functioning in a wide range of social and functional domains. 
It appears to measure more diverse, subtle and specific aspects of social behaviours than the 
GAF, and is possibly more independent of clinical symptoms. Difficulties related to social 
functioning is present already after a first treatment episode in BD, and functioning is 
perceived as impaired among both clinicians and patients. This implies that not only the 
management of clinical symptoms but also that therapeutic strategies are needed to 
improve the functional recovery of BD patients. The SFS could be a useful tool in assessing 
social functioning in several domains, and detect changes in functioning during the course of 
treatment. 
 
 
 
 
5.4. Methodological issues 
5.4.1. Study population, sample representativity 
 
The clinical samples included in the current three papers as part of the TOP study 
population, were recruited consecutively from a naturalistic treatment setting. All patients 
were recruited from out- and inpatient units across the four largest psychiatric hospitals in 
Oslo and the surrounding area. The Norwegian mental health care system is based on 
catchment area based patient admittance, and offers public mental health care to all 
individuals with mental illness within the given area. The absence of private mental health 
care hospitals or units in Norway suggests that the study population is to a large extent 
representative for individuals with BD or schizophrenia receiving treatment from psychiatric 
units.  
Patient inclusion was based on referrals from their treating clinicians, thus dependent on the 
clinicians’ initial assessment of which patients would be suitable candidates for the study, 
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and their understanding and positive attitude towards the aim of including all eligible 
patients in the study. To ensure the inclusion of as many patients as possible, the TOP study 
clinical assessment team members had their base in one or two clinics where they attended 
regular staff meetings reminding clinical staff of the ongoing studies and discussing possible 
cases.  
 
It is possible that participants with a positive attitude towards research or ‘higher 
functioning’ individuals with academic interest were more likely to take part in the study. 
This is supported by the fact that both the clinical and healthy control participants had a 
relatively high IQ compared to other studies in the field, but it could also suggest that 
outpatients and non-acute inpatients are better functioning than chronic hospital cohorts 
often used in other studies. The exclusion criteria for the study aimed at controlling the 
effect of medical problems, learning disabilities (IQ below 70) and poor Norwegian skills 
across clinical and control participants, as well as own or family history of psychiatric 
disorder or substance abuse in healthy controls. This will also have excluded those with 
poorest functioning. Due to the personal data filing system act, it is not possible to register 
characteristics of patients refusing to participate in research studies. We can only speculate 
in what the reasons for declining might be, like a poorer illness insight, more persecutory 
symptoms (especially for the schizophrenia patients) or not wishing to be associated with a 
mental illness. These factors are however common to all studies based on informed consent. 
 
The term first contact mania was used to define the overall patient sample in paper 2 and 3. 
The definition is somewhat challenging. The participants were characterized as first contact 
mania if they met the diagnostic criteria for DSM-IV BD I disorder, and were or had been 
receiving their first adequate treatment for a manic or mixed episode no more than 12 
months before inclusion. Because the patients might have had multiple depressive episodes 
or even unidentified and untreated manic episodes prior to inclusion, the clinical 
characteristics of the sample varied considerably. However, this is in line with the small 
amount of previous studies of first-episode BD, which also suggest that early BD patients are 
difficult to identify and engage in research studies compared to other first-episode psychotic 
disorders. Possible reasons for this could be that the persons with early symptoms of BD do 
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not seek specialized health care and are being treated by their general practitioner/family 
physician, or that initial depressive episodes are not recognized as BD.  More restricted 
criteria for a first episode, for instance no previous episodes of elevated mood would also 
limit the sample, both regarding statistical power but also in respect to its generalizability to 
clinical samples.  
To assure a representative clinical sample there was no a priori control of potential clinical 
confounders such as the presence of current symptoms, substance abuse and use of 
medication. Consequently, the degree of present symptoms varied from symptom-free to 
severe symptoms, especially depressive symptoms, duration of illness varied from having 
had one or a few episodes to multiple episodes, and the extent of substance abuse and 
medication use also varied. As a result, the findings in this thesis should be generalizable to a 
clinically heterogeneous sample of individuals with BD and SZ receiving treatment as usual in 
a mental health care setting. 
 
 
 
5.4.2. Possible confounders 
 
Because this is a naturalistic study, there is little control with potential confounding 
variables. There was also little a priori control by initial study design as we aimed to include 
as many persons with first contact mania as possible. However we tried carefully to identify 
potential confounders. 
 
Gender, age, IQ and education are known to influence neurocognitive test results. Men have 
shown a better performance on some visuospatial tasks, while women perform better on 
some verbal tasks (Halpern, 1997; Kern et al., 2008).  Age and education have been 
associated with lower cognitive performance with increasing age and lower education (Kern 
et al., 2008; Schaie, 1994). In paper 2 and 3 the first contact mania and healthy control 
groups were therefore matched for age, gender and education. Although not matched for 
IQ, the BD group did not differ from healthy controls on both premorbid IQ (NART) or full 
scale IQ (WASI). IQ below 70 was controlled for by the study design in all three studies.   
61 
 
 
Age (Tohen et al., 2000) and gender (Abel et al., 2010) have been shown to affect social 
functioning in severe mental illnesses. Gender differences have also been reported when 
using the SFS; with women reporting better functioning than men (Vaskinn et al., 2011). In 
the first paper, the three groups – SZ, BD and HC were not deliberately matched, however 
they did not differ in gender distribution, but the BD group was significantly older than the 
other two groups. The three groups also differed significantly from each other on IQ in the 
expected order; SZ < BD < HC. The SZ group had also significantly less education than the 
other groups. As schizophrenia patients have been shown to have a lower IQ in several 
studies (Urfer-Parnas et al. 2010) this could be related to illness specific features. The fact 
that the groups differed significantly in age and IQ in paper 1 could be a source of error. 
However, neither age nor IQ were significantly correlated with the SFS or the GAF-F, and 
only a modest significant correlation was found for sex and the GAF-F, suggesting they did 
not confound the main results. 
 
There are a number of clinical variables that have been known to influence both 
neurocognition and social functioning in BD. 
Clinical symptoms, such as manic or depressive states, have been shown to have a significant 
effect on neurocognitive performance in BD (Kurtz & Gerraty, 2009), as well as the number 
of episodes and duration of illness (Robinson and Ferrier, 2006). Several studies in the field 
have therefore used symptom free samples in order to control the effect of current 
symptoms on neurocognitive functioning (Bora et al., 2009; Torres et al., 2007). This is 
important in order to show that neurocognitive dysfunction is trait rather than state specific. 
However, the aim of paper 2 was to assess neurocognition in a naturalistic clinical setting 
and explore the possible relationship between symptoms and other early illness 
characteristics and neurocognitive functioning. It was therefore essential to include a sample 
with adequate variation. Depressive symptoms was the most frequent symptoms in this 
sample; nearly 60% of the total BD sample had depressive symptoms varying from mild to 
very severe symptoms, but little or no manic or psychotic symptoms. Although some trends 
towards significance was noticed, no significant correlations between early phase clinical 
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characteristics and neurocognition were found, suggesting that level of current symptoms 
did not explain the neurocognitive group differences between BD and HC participants. 
 
Two recent reviews found a number of clinical factors associated with poor social 
functioning in BD, including depressive symptoms, psychotic features, early onset, number 
of hospitalizations, and anxiety (Huxley & Baldessarini, 2007; Sanchez-Moreno et al., 2009), 
suggesting that a more adverse clinical course may be related to social dysfunction. In paper 
1, both SZ and BD sample were on average mildly depressed and in paper 3 as previously 
mentioned more than half of all participants had variyng degrees of depressive 
symptomatology. During depressive episodes, people with BD tend to display negative 
cognitive styles comparable to persons with unipolar depression, and this pattern has been 
demonstrated across measures of how people regard themselves, their life events, and their 
need to accomplish (Johnson and Tran, 2007). It is not unlikely that a negative cognitive style 
might have biased depressed individuals to rate themselves as poorer functioning than they 
actually are. Depressive symptoms are in addition associated with social withdrawal, 
decreased energy, low self-esteem etc. that also influence social behavior.  
 
Substance abuse has been reported to both improve and reduce neurocognitive functioning 
(Balanza-Martinez et al., 2010; Ringen et al., 2009) and to reduce social functioning in BD 
(Huxley & Baldessarini, 2007; Lagerberg et al., 2010). We did, however, not exclude patients 
with any substance abuse, in order to assure a representative clinical sample. Regarding 
cannabis use, the most frequently used drug in the BD group, 55% of the total sample of BD 
participants reported having ever used cannabis during their lifetime. Only 4 patients in the 
FM group and 2 patients in the PM group had ongoing substance abuse or dependency 
(including alcohol). When removing these patients from the analyses in article 2, results 
remained unchanged and thus ongoing substance abuse was not found to have a significant 
impact on neurocognitive functioning. 
Medication use may affect neurocognitive functioning in BD, and the risk for medication-
associated cognitive side effects seems to increase with polypharmacy and the use of high 
doses (Balanza-Martinez et al., 2010). While antipsychotic medications have been related to 
significant cognitive deficits in most cognitive tasks (Torent et al., 2011), lithium has been 
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associated with lower impairment (Martinez-Aran et al., 2007). Nearly all of the patients in 
the present investigations were on medication compared to none of the healthy controls. 
Only 14% of the total BD sample in paper 2 and 3 were unmedicated, the remaining 
participants received different combinations of medications. A relatively large proportion of 
the total sample (73%) received antipsychotic medications. Regarding psychomotor speed 
deficits for instance, we cannot rule out the effects of medications on the performance. 
Although several studies have found that treatment with antipsychotic medication, 
especially chlorpromazine (Knowles et al., 2010) cause an impairment in psychomotor 
functioning, other studies have detected an improvement of psychomotor speed after both 
atypical and conventional antipsychotic treatment in schizophrenia (Morrens et al., 2006). 
We did in fact find a significant positive correlation between defined daily dose of 
antipsychotic medication and the Grooved Pegboard test (p = 0.004), suggesting a slower 
performance of the motor speed task with increased medication dose. The impact of lithium 
on impairment of psychomotor speed tasks have been reported in a review (Pachet et al., 
2003). However, as only nine patients were on lithium at the time of assessment, it is 
unlikely that the impairment would be a result of lithium treatment only. The effects of 
medications are also likely to be related to illness severity, for instance use of antipsychotic 
medications naturally has a very high degree of association with history of psychosis.  
 
 
5.4.3. Measurements 
 
Only standardized measures that are widely accepted, that overlap with other studies in the 
field, and have been tested for good psychometric properties have been used in these 
studies. The SCID-I interview has been found to yield highly reliable diagnosis for most axis I 
and II disorders (Segal et al., 1994). The IDS-C has satisfactory psychometric properties (Rush 
et al., 1996) and appears applicable to both in- and outpatients with different affective 
disorders (Rush et al., 1986). The PANSS is the most widely used measure of symptom 
severity in schizophrenia, and have good psychometric properties (Santor et al., 2007). The 
YMRS have also good reliability, validity and sensitivity (Young et al., 1978) and is the most 
commonly used scale for assessing treatment response in mania (Poolsup et al., 1999). 
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There are several challenges related to the measuring of social functioning. The use of rating 
scales to measure social functioning indicates that subjective and qualitative data are being 
quantified by the participants or the clinician. The operationalization of social functioning is 
also difficult, as it involves multiple domains. An individual might show good functioning in 
one domain and impairment in others, and this will not be noticeable in rating scales such as 
the GAF, as functioning in several areas will be averaged into one simple score. Finally, the 
measurement of social functioning also involves more theoretical questions of what good 
social functioning really entails. The fact that we used both self-rating and clinician-rating 
scales was regarded an advantage, as the likelihood of patients symptoms affecting self-
rating was of a concern. The GAF was therefore used as a ‘gold standard’ in addition to 
objective observable measures of social functioning (such as having a job) when conducting 
the validation study of the Social Functioning Scale. The GAF is widely used to assess 
psychological, social and occupational functioning. The inter-rater reliability of GAF ratings, 
performed by trained clinicians or in research settings, has been shown to be excellent 
(Hilsenroth et al., 2000; Vatnaland et al., 2007). The validity and reliability of the GAF-scale in 
clinical practice have only scarcely been studied in naturalistic samples, however one study 
found rather poor inter-rater reliability of the GAF as well as poor discriminant validity with 
disease severity in a large naturalistic sample of outpatients with major depressive disorder 
(Grootenboer et al., 2011). Both symptom and function scores of the split GAF (Pedersen et 
al., 2007) have been found highly consistent across raters and units. For research purposes 
and with trained raters, the GAF is thus a reliable instrument.  
 
The purpose of paper 1 was to assess the reliability and validity of the Norwegian version of 
the Social Functioning Scale for patients with schizophrenia, bipolar disorder and healthy 
controls. Although the study concluded that the SFS was a valid and reliable tool for 
measuring social functioning in severe mental illnesses also in Norway, there are 
methodological issues that need to be addressed. The study found low inter-item 
correlations, which might be a limitation of the scale. However, as the alpha values were 
satisfactory for all scales, the implication of reduced inter-item correlation is uncertain. Self-
evaluation has been shown to be particularly impaired in people with schizophrenia, and 
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those impairments could lead to inaccurate estimation of skill levels (Harvey et al., 2007). On 
the other hand, a comparison between self-report ratings and ratings from informants show 
that agreement is highest for observable aspects such as functioning, and lowest for 
psychological aspects (Becchi et al., 2004). The statistically significant differences between 
the schizophrenia group and the BD group on all sub scales of the SFS suggests a real 
difference in social functioning among the groups rather than a response bias, as all 
observable measures such as employment status and living situation also differed 
significantly between the patient groups, favoring BD patients.  
 
The use of different neuropsychological tests in various studies might be a disadvantage for 
the studies of neurocognition in BD, making direct comparisons somewhat challenging. 
Although cognitive impairment is recognized as an important clinical feature of BD, there is 
no standard cognitive test battery that has been developed for BD research. The MATRICS 
(Measurement And Treatment Research to Improve Cognition in Schizophrenia; 
Nuechterlein et al., 2008) test battery increasingly used in schizophrenia research also have 
been judged suitable for patients with BD, even if other tasks including more complex verbal 
learning measures and tests of executive functioning should probably also be considered 
(Yatham et al., 2010). The neuropsychological tests used in this study are widely accepted 
and overlap with many previous studies in the field. However, the assignment of specific 
tests into different domains is to some extent controversial, as many tests call upon several 
functions. There are also a degree of overlap between domains, for instance memory and 
executive functioning have been reported to share 50-60% of variance (Duff et al., 2005). As 
psychological attributes such as cognitive abilities cannot be measures directly, we need to 
obtain a sample of behavior that can be quantified and represented in numerical scores. 
Concerns about the ecological validity of tests and predictions have been addressed by many 
researchers (Lezak, 2004). Cognitive performance in a structured setting with few 
distractions may not reflect cognitive functioning in everyday life, with the distractions that 
are usually present in more natural settings. Some cognitive functions are also difficult to 
reflect in a laboratory setting, such as the ability to initiate goal directed behavior (executive 
functioning). Lack of motivation or anxiety in the test situation may have a negative 
influence on test performance. As patients underwent quite extensive clinical and cognitive 
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examinations there was a concern that they would experience the involvement in the study 
as exhausting. We tried to address the problem with poor motivation by only include 
participants with a valid test performance assessed with a forced recognition task (Delis et 
al., 2004). 
 
 
5.4.4. Ethical considerations 
 
The TOP study is approved by the Regional Committee for Medical Research Ethics, and all 
participants gave their written informed consent before entering the study. Although the 
ethical sides of the project are officially approved, some aspects will be addressed. The 
patients in all three studies have severe mental illnesses with symptoms that might interfere 
with reality testing, making “informed consent” a possible challenge. Therefore, their 
psychiatric condition was thoroughly evaluated by their treating clinician in collaboration 
with the research fellow before asking the patient to participate. Patients were also told that 
they could leave the study at any time, with no questions asked, and that this would not 
have any consequences for their further treatment in the clinic. Both clinical and 
neuropsychological assessments are extensive, time consuming and probably tiring for the 
patients. The assessments were often broken down to several sessions on different days. 
Interviews were carried out at the patients’ respective clinics or research offices, depending 
on what was most convenient for the patients. Patients were also offered taxi transportation 
to the research office if necessary. When assessments were completed, written reports from 
the neuropsychological testing and the clinical interview including a DSM-IV diagnosis were 
sent to the treating clinician with the patients consent. Patients were also offered an 
appointment with both interviewer and treating clinician present, where the information 
from the reports were presented and discussed. The general impression was that both the 
written reports and the feedback session were appreciated and considered useful by both 
clinicians and patients. 
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6. STRENGTHS, LIMITATIONS AND FUTURE RESEARCH 
 
Strengths and limitations of the study have already been directly and indirectly discussed, 
but the main issues deserve to be highlighted. This is one of the first studies that have 
investigated the relationship between baseline neurocognitive functioning and baseline 
social functioning in first contact mania. To this date, only one previous study (Torres et al., 
2011) has looked at this relationship in a first-episode BD sample. Recruitment through the 
Norwegian public mental health care system with a catchment area patient admittance 
system may have resulted in a relatively high degree of representativity compared to studies 
that have recruited from private clinics with more selected populations. Social functioning 
was examined using both clinician ratings and patients’ self-report. This captures both 
patients’ subjective experience in addition to an externally rated evaluation of their 
functional level. The instrument used to measure self-rated social functioning, the Social 
Functioning Scale, is validated on a Norwegian BD sample that is not overlapping with the 
first-episode patients. Rather than simply comparing the mean neurocognitive function for 
the clinical group to a sample of healthy controls, we investigated how many in each group 
had severe or ‘clinically significant’ cognitive impairment. This might give us an idea of how 
many patients who will actually experience difficulties in their daily life as a result of 
cognitive impairment. 
 
One of the main limitations is that although the patients with BD were characterized as first 
contact mania because they had not received adequate treatment for a first manic episode 
before, many of them had had previous episodes with both elevated and depressed mood. 
We tried to attend to this by separating the patients into a first manic- and a previous 
untreated manic episodes group. Both the clinical and control samples have relatively high 
IQ compared to most previous findings, suggesting that we might have recruited fairly high 
functioning groups. Because the data is cross-sectional we cannot make inferences about 
causal relationships. The sample was not euthymic. 
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As this is one of the first studies to investigate the relationship between social functioning 
and neurocognition early in the course of BD, future studies should seek to replicate the 
findings from this particular study to support or disconfirm the findings in other first-episode 
mania samples. The fact that both our study and Torres and colleagues (2011) did not detect 
a significant relationship between neurocognitive functioning and social functioning in first-
episode BD might be due to methodological issues, or it may be that this relationship is not 
detectable until the illness have progressed. A matched sample of multiple-episode BD 
patients would also be useful as a comparison group to look at difference in magnitude of 
neurocognitive dysfunction, and longitudinal studies of first-episode patients might be 
valuable to study illness progression. Future research should also investigate the use of 
cognitive remediation for persons with BD. Finally, the impact of a wider range of factors 
that might mediate the relationship between neurocognition, symptoms and social 
functioning should be explored, such as self-esteem, social cognition, personal attitudes and 
social support. 
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7. CONCLUSION 
 
This thesis has investigated whether patients with BD recently treated for a first manic 
episode has neurocognitive deficits and social dysfunction, and to what extent these 
variables are related. 
Firstly, the findings suggest that neurocognitive dysfunction is present early in the course of 
BD and reaches the level of clinical significance in a subgroup of individuals. Compared with 
multiple-episode patients the findings also suggest that cognitive impairment in certain 
domains may progress with advancing illness course, while others may already be impaired 
at illness onset.  
Secondly, the findings suggest that impairment of social functioning in BD is present already 
after a first manic episode, and is associated with a number of clinical variables especially 
with depressive symptoms. Taken together, the findings from premorbid- and current social 
functioning suggests that impairments in functioning are related mainly to illness onset and 
the clinical symptoms associated with having BD. Thirdly, the findings did not support 
previous reports from non-first episode BD samples of neurocognition as a mediator for 
social functioning. 
Finally, the findings underline the importance of assessing neurocognitive functioning in 
patients with BD, and suggest that at least a subgroup of patients are in need of treatment 
aimed at enhancing cognitive functioning. Additionally, complete functional recovery after 
an episode of depression should also be the goal of treatment as enduring residual 
symptoms most likely lead to long-term psychosocial impairment. Therapeutic strategies 
might also be needed to improve the functional recovery of BD patients. The SFS could be a 
useful tool in assessing social functioning in several domains, and detect changes in 
functioning during the course of treatment. 
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Objectives: Cognitive dysfunction in bipolar disorder (BD) is well established in the literature, 
however there are few studies of neurocognition in patients early in the course of the illness. In this 
study we compare neurocognitive function in a cohort of first contact mania patients with a healthy 
control group, matched for age, gender and education. 
Methods: Patients with a first manic episode (FM, n= 34) or previous untreated manic episodes (PM, 
n= 21) were neuropsychologically tested following  their first treated manic episode. A hundred and 
ten matched healthy control comparison subjects were also tested. The following cognitive domains 
were evaluated: verbal and visual learning and memory, attention, processing speed, executive 
functioning and IQ. Results were corrected for speed of processing differences, and were compared 
with previously reported results for multiple-episode bipolar disorder patients. 
Results: BD patients early in their disease course showed impairments in psychomotor speed, 
attention, learning and memory, executive functioning and IQ. When controlling for speed of 
processing, measures of visuoconstructive reasoning and motor dexterity remained statistically 
significant.  18% of FM and 16% of PM patients were found to have clinically significant 
neurocognitive impairment. No significant relationship between clinical symptoms and 
neurocognition was found. The  first contact mania patients studied were found to  have   smaller 
neurocognitive deficits compared to multiple-episode patients in previous studies. 
Conclusion: Neurocognitive dysfunction is present in early  bipolar disorder and is  clinically 
significant for a proportion of patients. Our findings also suggest that  neurocognitive dysfunction 
may increase with illness progression. 
(246 words) 
 
Keywords: bipolar disorder, first episode, mania, neurocognition, processing speed 
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Introduction 
 Cognitive dysfunction in bipolar disorder (BD) is well established in the literature. Meta-
studies of neurocognition in multiple-episode BD patients have demonstrated deficits in standardized 
neuropsychological measures,  including executive functioning, verbal learning and memory, 
attention and processing speed that persist during periods of euthymia (1-4). Results from previous 
studies from the TOP project show that  BD patients have reduced performance in all measures of 
verbal memory , and in most measures of attention and executive functioning compared to healthy 
controls (5). However, the proportion of patients with BD who have clinically significant cognitive 
impairment  varies between studies and is  dependent upon the definition of neurocognitive 
impairment used, the  measures of impairment employed and the  proportion of BD subtypes (I and 
II) in the sample. Studies have reported clinically significant impairment (< 1.5 SD below control 
group mean or scoring below the 5th percentile, respectively) in BD type I,  varying from 3-36% (5) to 
3.2-41.9% (6) , suggesting that more than half of people with BD do not experience cognitive 
difficulties. Several clinical factors may contribute to the variation in cognitive functioning,  including 
a history of psychotic episodes (7), the number of previous mood episodes, the number of hospital 
admissions, illness duration (8; 9),  age of  onset of symptoms and  duration of treatment delay (10; 
11; 12). This indicates that cognitive dysfunction increases with illness progression, as suggested by a  
recent study, that included patients with long treatment histories, that showed an increase in 
cognitive dysfunction with an increase in  number of manic episodes (13). However, it is possible that 
fewer episodes and good cognitive functioning over the course of the illness  are expressions of a 
more benign form of BD  rather than being causally related to each other. Evidence for progressive 
cognitive decline in BD is thus still inconclusive. 
 Neurodegenerative models have been used to explain neurocognitive deficits in at least some 
domains  (14). Whether neurocognitive deficits reflect a global cognitive dysfunction or are a 
consequence of a primary deficit in  core cognitive functioning remains unclear.  
A meta-analysis has shown processing speed deficits to be present in patients with schizophrenia 
(15) and also in a twin sample of BD I patients (16). Deficits in processing speed in patients with 
schizophrenia have been shown to be associated with impairments in working memory and verbal 
learning (17).  This adds to a growing body of work demonstrating the importance of processing 
speed to cognitive functioning and clinical outcome in severe mental disorders.  
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Most previous studies of neurocognition in BD have recruited patients with treated, multiple-episode 
BD. There are few studies with a cohort of patients early in the course of their disease. The 
recrutiment of a cohort with  first-episode mania is difficult as first-episode mania is relatively rare in 
clinical practice.  As it is not possible to give a diagnosis of BD type I until the patient has experienced 
their first manic episode, in most studies ‘early in the course of the illness’ denotes ‘from the point of 
first treatment’. Two studies comparing patients with first episode BD with healthy controls found 
signs of executive dysfunction, but the sample sizes were small (18; 19). Studies comparing first-
episode BD groups with other first-episode psychotic disorders, such as schizophrenia, have found 
either less severe cognitive dysfunction in BD (20; 21), or no clear group differences between the 
patient groups. There were differences in cognitive dysfuction in these groups compared to healthy 
controls (22; 23). A study  comparing neurocognition in symptomatic first-episode BD patients with  
multiple-episode BD patients found no differences between the groups (18).A similar study  
surprisingly found poorer functioning in first-episode patients (24). However a bias may have present 
in this study as patient groups  were not matched according to significant demographic and clinical 
variables. These studies also included small patient samples (N= 19 to 32), making the  interpretation 
of findings and covariate analysis difficult. A recent study including a larger patient group (N= 45) (25) 
reported moderate effect size differences between euthymic BD participants who had recently 
experienced their first manic episode and healthy subjects. The measures employed assessed 
sustained attention, learning and memory, and nonverbal/spatial reasoning. The percentage of 
patients showing clinically significant cognitive impairment, i.e 1.5 SD below the mean of the control 
group, varied from 11-31% across tests. When comparing this data to previous  meta-studies of 
multiple-episode euthymic BD samples (2; 3), the results indicate that the magnitude of cognitive 
impairment in first-episode BD was comparable to that found in multiple-episode BD for tasks that 
included premorbid/verbal intellectual ability and attention/processing speed. For  tasks such as 
verbal memory and executive functioning there were consistently smaller cognitive deficits in first-
episode patients (25). More studies on patients early in their disease course are necessary  as this is a  
period where intervention may attenuate or prevent the changes that appear to emerge with 
chronicity (26).  
The current study used a relatively large  cohort of patients at first treatment for a manic episode 
(first contact mania patients). This cohort is comprised of two subgroups; one with no previous manic 
episodes (FM), and another consisting of patients who  had one or more previous  untreated manic 
episodes (PM).  
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The aims of the study was to investigate neurocognitive function in these two BD subgroups by 
comparing them to a healthy control group matched by age, gender and level of education, to 
examine the severity of the impairments, whether the impairments were clinically significant and  
whether patients were deficient in all domains or in just a number of domains. In addition, we 
investigated whether group differences can be explained by differences in processing speed. Another 
specific aim of the study was to examine if cognitive impairments are related to premorbid and early 
illness characteristics, in particular age at onset, duration of untreated illness and number of previous 
mood episodes (manic, depressive and psychotic). 
 
 
Materials and methods 
 
Participants 
Participants with BD were recruited consecutively  to the Early Bipolar Disorder Study,  a section of 
the Thematically Organized Psychosis (TOP) Study group, from psychiatric inpatient and outpatient 
units at the major hospitals in the Oslo area, Norway. Patients were considered eligible for this 
particular study (i.e. first contact mania patients) if they met the diagnostic criteria for DSM-IV 
bipolar I disorder and were receiving their first adequate treatment for a manic episode. Since 
acutely manic patients are not always able to give informed consent, patients were included up to 
one year after the start of their first treatment. Patients were included if they had experienced 
previously untreated manic episodes, and  if they had had a previous major depressive episode, 
whether treated or untreated. Fifty five patients in total met these inclusion criteria. 
 The cohort was divided into two subgroups. The Previous Manic episode subgroup (PM) consisted of 
patients who had had previous manic episodes that were neither identified nor adequately treated 
as such. The First Manic episode subgroup (FM) had only experienced the manic episode with which 
they presented. Healthy control (HC) participants were randomly selected from national statistical 
records from the same catchment area as the patients, and contacted by letter inviting them to 
participate. HC participants were excluded if they or any close relative had a lifetime history of a 
severe psychiatric disorder (schizophrenia, bipolar disorder and major depression), or if they had a 
history of substance abuse or dependency in the previous six months. For the purpose of this study 
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consecutive HC participants were matched in a ratio of 2:1 to patients on age, sex and education. The 
study was approved by the Regional Committee for Medical Research Ethics and the Norwegian Data 
Inspectorate. All patients received a complete description of the study before giving written, 
informed consent. The exclusion criteria for all groups were a history of hospitalization for  head 
injury, neurological disorder, unstable or uncontrolled medical condition that interferes with brain 
function, IQ below 70 and age outside the range of 17-60 years. The participants also had to have 
Norwegian as their first language or have received their compulsory schooling in Norway, and  to 
have scored 15 or above on the forced recognition trial in the California Verbal Learning Test (CVLT-II) 
(27). 
  
Clinical assessment 
Clinical assessment was carried out by trained psychiatrists and clinical psychologists. Diagnosis was 
based on the Structured Clinical Interview for DSM-IV Axis I disorders (SCID-I) (28) and available 
medical records. Inter-rater reliability for diagnosis had an overall kappa-score of 0.77 (95% CI 
[0.60,0.94]) (29). Age at onset, polarity of first presenting episode and number of episodes were 
determined from the clinical interview and through examination of medical records. Polarity of first 
presenting episode was defined retrospectively as the polarity of the first SCID verified episode as 
indicated in the SCID protocol, and age at onset was the age at which the person had experienced 
this episode. Information about previous psychotic episodes (history of psychosis) was based on 
information from the SCID interview and medical records. The level of current symptomatology was 
defined based on the following scales: current depressive symptoms were rated using the Inventory 
of Depressive Symptoms-Clinician rated (IDS-C) (30), current manic symptoms were rated using the 
Young Mania Rating Scale (YMRS) (31), and current positive and negative symptoms were rated using 
the Positive And Negative Syndrome Scale (PANSS) (32).  The effects of medication on cognitive 
performance on the day of testing was assessed using Defined Daily Dosages as the measure of the 
level of antipsychotic medication. 
 
Neurocognitive assessment 
Neurocognitive assessment was carried out by psychologists trained in standardized 
neuropsychological testing. A three-hour test battery was administered in a fixed order, including 
108 
 
two breaks. Measures included in this study have previously been found to be sensitive to 
dysfunction in schizophrenia and bipolar spectrum disorders (7). 
Learning and memory was measured using three tests. The  Logical Memory test (33), part of the 
Wechsler Memory Scale (WMS-III) (verbal learning and verbal recall);  the California Verbal Learning 
Test (CVLT-II) (27), verbal learning and long delay free recall, and the Rey-Osterrieth Complex Figure 
Test (34), delayed recall.  
Psychomotor speed was assessed with the following tests: Grooved Pegboard (35), measuring the  
average of left and right hand combined; Digit Symbol Coding, as contained in the Wechsler Adult 
Intelligence Scale (WAIS-III) (36), and the color naming task and the word reading task from the 
Color-Word Interference Test as contained in the  Delis Kaplan Executive Functioning System (D-
KEFS)  (37).  
Attention and working memory was assessed using the Digit Span and the Letter-Number sequencing 
from the Wechsler Adult Intelligence Scale (WAIS-III) (36) and the computer based Bergen n-back 
Test (N-back) (38)  using d’ as a measure of attention/working memory 
Executive function was assessed using subtests of verbal fluency (letter fluency, category fluency and 
category switching) from the D-KEFS battery (37); the inhibition and inhibition/switching subtests 
from the Color-Word Interference Test contained in the D-KEFS (37) and the Wisconsin Card Sorting 
Test (39) measuring total errors, perseverative responses and number of correct categories achieved. 
Premorbid IQ was measured using the National Adult Reading Test, Norwegian version (40), and IQ 
was assessed with the Wechsler Abbreviated Scale of Intelligence (WASI) (41) using the subtests 
Vocabulary, Similarities, Block Design and Matrix reasoning.  
Statistical analysis 
The Statistical Package for the Social Sciences (SPSS for Windows, version 16.0, SPSS Inc., Chicago, IL, 
USA) was used for all statistical analysis. Between-subjects univariate analysis of variance (ANOVA) 
and chi-square analysis were used to compare group differences on demographic characteristics. The 
independent samples t-test or the Mann-Whitney U test were used to investigate group differences 
between the FM and PM groups with regard to clinical characteristics. Group differences in 
neuropsychological test performance was analysed using between-subjects univariate ANOVA with 
effect size (eta squared) of group differences and Scheffès post hoc tests. Bonferroni corrections 
were applied for all cognitive domains. Analysis of covariance (MANCOVA) was conducted by 
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entering Digit Symbol Coding as a covariate to investigate if, when psychomotor speed was 
controlled for,  group differences in neurocognitive performance remained significant. In order to 
report effect sizes of the neurocognitive dysfunction, z-scores were constructed for each cognitive 
subscore based on the means and standard deviation of the control group, and a mean z-score for 
each domain was calculated. The proportion of participants with clinically significant cognitive 
impairment, defined as neurocognitive scores 1.5 SD below the average of the healthy control group 
was calculated, thus capturing participants performing below the normative seventh percentile level. 
Chi-square analysis was used to investigate group differences in clinical impairment. Non-parametric 
correlations (Spearman’s rho) were used to assess the relationship between neurocognitive variables 
and clinical variables, with a level of significance determined at .01 due to multiple comparisons. Raw 
scores for all neurocognitive tests were reported.   
 
 
Results 
Demographic and clinical characteristics of HC and the FM and PM groups  are presented in table 1 
and 2 (TABLE 1+2 IN HERE). There were no group differences between the FM, PM and HC 
participants regarding age, education, gender or premorbid IQ (NART). 
 
 
Clinical characteristics 
The FM and PM groups did not differ significantly with regard to the polarity of their first episode, 
current clinical symptoms, or incidence of lifetime psychosis with 73% of the FM group versus 66% of 
the PM group having experienced psychotic symptoms. The number of patients with ongoing SCID-
verified substance abuse or dependency did not differ significantly between the FM group (4 
patients) and the PM group (2 patients).  The groups differed significantly on age at onset of their 
first affective episode. The PM group was on average six years younger than the FM group at illness 
onset. The PM group also had significantly more depressive, manic and psychotic episodes compared 
to the FM group, and a significantly greater number of hospitalizations. There were also significant 
differences in treatment delay (time from first episode to start of adequate treatment), with an 
average of 1 year for the FM group and 8 years for the PM group. The groups did not differ 
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significantly regarding the type of medication they used, but significantly more patients in the PM 
group were unmedicated.  
 
Neurocognitive performance. 
The groups’ mean performance for each neurocognitive measure and the respective analyses of 
variance with effect size estimates and Scheffès post-hoc tests are presented in table 3 (TABLE 3 IN 
HERE). Significant group differences were found in all cognitive domains with differences reaching 
the level of nominal significance in eleven of the single measures. Eight single measures remained 
statistically significant after Bonferroni-corrections. 
 The most statistically significant differences between the groups were with regard to psychomotor 
speed with all measures, except word reading completion time, lower in both the FM and PM groups 
compared with the HC group with medium to large effect sizes. Two of four measures of attention 
and working memory were significantly different in the clinical groups in comparison with healthy 
control group. There was a medium effect size difference between the FM group and the HC group 
on Digit Span backwards, and both clinical groups differed significantly, with medium effect sizes, 
from the HC group on the Letter-Number sequencing task. 
The domains with the least significant differences between the groups were verbal learning and 
memory, executive functioning, IQ. The FM group had significantly lower scores than the HC group 
on CVLT-II recall, and both patient groups differed significantly from the HC group on the inhibition 
condition of the Color-Word interference test. A trend towards significance was also found for the 
Rey-Osterrieth Complex Figure Test and the inhibition-switching condition of the Color-Word 
interference test in both FM and PM groups in comparison with the HC group. Of the WASI subtests, 
only Block Design was statistically significantly lower in the two clinical groups, while a trend towards 
significance was found in the WASI subtest Matrix reasoning. Effect sizes for the  statistically 
significant differences were small to medium. 
After adjusting for psychomotor speed (Digit Symbol Coding), three of the eight statistically 
significant neurocognitive measures remained significant. These were Letter-Number sequencing, 
Grooved Pegboard and Block Design. Only the two latter measures remained statistically significant 
after Bonferroni corrections. Effect sizes were also reduced by 50% after Bonferroni corrections.  
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Clinically significant impairments 
The proportion of FM, PM and HC participants with cognitive impairment within a clinically 
significant range for each subscore is shown in table 4 (TABLE 4 IN HERE).  On average, 18% of the FM 
group and 16% of the PM group, compared with 7% of the HC group were considered clinically 
impaired across cognitive measures. With regard to learning and memory tasks, 23% of FM and 14% 
of PM compared to 7% of the HCs had clinically significant impairment.  Impairment of psychomotor 
speed was found in 21% of FM and 25% of PM participants compared to 7% of HC participants. 13% 
of FM and 12% of PM participants were considered clinically significantly impaired in attention and 
working memory, whereas 4% of HC participants had impairment in these tasks. Regarding executive 
functioning, 15% of FM, 11% of PM and 6% of HC participants had clinically significantly cognitive 
impairment. On the IQ measures, 17% and 19% of the FM and PM groups had impairment compared 
to 8% of HC participants. Overall, twice as many participants from the two bipolar disorder groups as 
healthy controls groups had clinically significant cognitive impairment. 
 
 Group differences in neurocognition between the FM and PM groups 
Neurocognition did not differ significantly between the FM and PM groups on most measures. 
However, the FM group was found to be significantly different from the HC group on CVLT-II recall 
and Digit Span backwards. The FM group was also significantly more impaired than the PM and HC 
groups on Logical Memory (learning condition), CVLT-II recall and Letter Number sequencing 
measures. The PM group was significantly more impaired than the FM and HC groups on Matrix 
Reasoning. The average proportion of clinically significant impaired patients was comparable in the 
FM and PM groups. 
 
 
The relationship between early phase clinical characteristics and neurocognition in first contact mania  
In order to investigate the influence of illness course and severity on neurocognitive performance, 
follow-up analysis was performed. The bivariate associations between clinical characteristics and 
neurocognitive functioning in the FM and PM groups combined are presented in table 5 (TABLE 5 IN 
HERE). There was a significant positive correlation between defined daily dose of antipsychotic 
medication and the Grooved Pegboard test (p= 0.004), suggesting a slower performance of the 
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motor speed task with increased medication dose. No other correlations between cognitive 
performance and clinical measures were deemed significant (p<0.01) although some trends (p< 0.05) 
towards significance were noticed. When investigating the potential influence of current symptoms 
we found a trend towards significance for the association between depressive symptoms, as 
measured by the IDS-C, and Verbal fluency set shift in a direction indicating that higher levels of 
depression were associated with a better performance. There was also a trend towards significance 
for depressive symptoms and Color-Word: color naming indicating that patients with more 
depressive symptoms needed a longer time to complete the task. Current elevated mood, duration 
of untreated illness and lifetime or current psychotic symptoms were not significantly related to any 
cognitive measures.   
 
 
 
Discussion 
 
The main finding of this study is that neurocognitive deficits are present in patients with BD  at the 
time of their first treatment for a manic episode. This applies both to patients with no previous manic 
episodes and to patients with previous untreated episodes. We found statistically significant 
differences between the FM and PM groups and the HC group on measures of verbal recall, 
psychomotor speed, attention, visuoconstructive reasoning and some aspects of executive 
functioning. These results strengthen findings from previous studies with smaller sample sizes (24; 
25). The groups were matched on age, gender and education, but not IQ. Of particular interest is that 
we did not find any differences in premorbid IQ (NART) between the BD groups and the HC group. 
Similar results have previously been reported in BD groups with a more chronic illness course (5). 
Despite differences in age at onset, number of episodes and treatment delay between the two BD 
patient groups they generally performed similarly on most neurocognitive measures and had the 
same level of clinically significant cognitive impairment.  Levels of cognitive impairment in first 
contact mania patients appear to be less extensive than levels reported in more chronic- or multiple 
episode BD patients (1-6; 9), indicating that neurocognitive decline continues over the course of the 
disorder. Comparing the combined FM and PM groups to a non-overlapping sample of patients with 
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multiple treated episodes from the TOP research project (5) provides a preliminary framework for 
determination of the longitudinal course of cognitive impairment of the illness. (FIGURE 1 IN HERE). 
 Figure 1 shows that the magnitude of dysfunction in first contact mania patients is comparable to 
that in multiple treated episode BD patients on certain measures of verbal recall (CVLT-II delayed 
recall) and executive functioning (Color-Word Interference test; subtest 3 and 4 combined). For the 
remaining tasks, including verbal learning (Logical Memory and CVLT-II learning), attention (Digit 
Span, Bergen n-back) and other measures of executive functioning (Verbal fluency, 3 subtests 
combined), consistently smaller cognitive deficits are present in first contact BD patients than in 
multiple treated episode BD patients. The results of  neuropsychological measures in a meta-analysis 
of 948 euthymic BD patients (42) were similar to those from the multiple treated patients (5). Both 
groups were slightly older than the first contact mania sample. The multiple treated episode patients 
were on average 38 years old and the sample from the meta-analysis was on average nearly 40 years 
old. This suggests that in certain domains, cognitive impairment progresses  with advancing illness 
course, while other domains may already be impaired at illness onset. However,  as some patients 
with BD are more in need of treatment and remain within the healthcare system, a selection bias 
may be present in these studies with an over representation of patients with severe BD. Longitudinal 
studies are necessary to fully investigate the development of neurocognitive dysfunction over the 
course of the illness.  
Contrary to expectations, there was a lack of associations between illness history variables, such as 
number of manic episodes or duration of untreated illness, and neurocognitive functioning. This 
might be due to a lack of statistical strength as the design of the study necessarily set more 
restrictions on the number of previous elevated mood episodes than previous studies on multiple-
episode patients. We found a trend towards a significant association between level of depression 
and one measure of executive functioning that is in line with previous findings.  Increased severity of 
depressive symptoms in unipolar major depression has been shown to be significantly associated 
with reduced cognitive performance across episodic memory, executive functioning and processing 
speed (43). In BD, depressive symptoms has been associated with dysfunctions in psychomotor 
speed, speed of information processing and attentional switching (44).  The findings of reduced 
verbal memory in healthy relatives of individuals with BD, indicating a genetic vulnerability to BD, 
(45; 46) suggest that some cognitive deficits might predate illness onset. Verbal learning and 
memory, especially long delayed recall, and verbal working memory are the most suitable cognitive 
endophenotypes to be used in genetic studies of BD (47).  
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The largest difference between patients with first episode BD and HC participants was in the area of 
psychomotor speed. This has previously been documented in the literature (2) and has also been 
observed in healthy family members (48;49) suggesting a heritable component to BD. When 
correcting for psychomotor speed (Digit symbol) only two neurocognitive measures, Grooved 
Pegboard and Block design, remained statistically significant. A third measure, Letter-Number 
sequencing, lost significance after Bonferroni correction. This suggests that motor speed, attentional 
and visuoconstructive measures are the most sensitive tests in this sample.  Many higher cognitive 
operations involve internal dynamics that are speed-dependent. The kind of slowed information 
processing measuresd by Digit Symbol has been suggested as a central feature of the cognitive 
impairment seen in schizophrenia (15).  Our findings are in line with a recently published paper by 
Antila and colleagues (50) who found that processing speed had a significant effect on nearly all 
other assessed cognitive functions among patients with BD I. 
 This study has several strengths and limitations. The main strength is the large and extensively 
characterized sample of patients who were early in the course of their treated illness. An associated 
weakness of the study was that as patients were assessed as close to the resolution of their first 
treated manic episode as possible, some were not truly euthymic but were deemed to be mildly 
depressed as per the average score on IDS-C. Cognitive performance can potentially be influenced by 
current symptomatology. However there were few, and in some cases contradictory, non-significant 
associations between depressive symptoms and neurocognitive functioning, suggesting a minimal 
influence of depressive symptoms on results. The age at onset and illness history measures were 
necessarily based on patients’ retrospective memory and may have been influenced by recall bias. 
Medication effects can potentially influence cognitive performance. We found a significant 
association between defined daily dose of antipsychotic medication and motor speed but no 
association for other, more cognitively demanding tasks.  
 
In conclusion, this study shows that neurocognitive dysfunction is present early in the course of BD 
and reaches the level of clinical significance in a subgroup of individuals. Comparing our results with 
those of studies of multiple-episode patients, the findings suggest that the neurocognitive 
dysfunction may increase with illness progression. 
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Abstract 
 
Purpose: To study the association between neurocognition and social functioning in patients 
having their first treatment contact for bipolar disorder. 
Methods: A total of 55 first contact patients, 34 with a first manic episode (FM) and 21 with 
previously untreated manic episodes (PM), and 110 healthy control subjects matched for 
age, sex and education to the patient group, completed  the Social Functioning Scale (SFS), a 
self-reported assessment  of social functioning. The patients’ level of functioning was rated 
by a clinician using the split Global Assessment of Functioning- Function scale (GAF-F), and 
they completed a broad neuropsychological test battery. 
Results: Both patient groups had significantly lower self-rated social functioning compared to 
healthy controls, measured by the SFS. In addition, PM patients reported significantly lower 
functioning than FM patients. In multivariate analyses exploring the relationship to clinical 
symptoms and neurocognition, current depressive symptoms and processing speed had an 
independent influence on self-rated social functioning, while only current psychotic 
symptoms had an independent relationship to clinician-rated social functioning. 
Conclusions: Social dysfunction was present in patients with BD already at first treatment 
contact episode, the main predictors of this being the severity of clinical symptoms. Patterns 
of association were different for self-rated compared to clinician-rated functioning. 
 
 
Keywords: social functioning; bipolar disorder; neurocognition; manic episode. 
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Introduction 
 
  
Bipolar disorder (BD) is one of the largest causes of disability in developed countries and 
ranks amongst the leading contributors to global burden of disease worldwide [1]. BD is 
considered to have a more favourable prognosis than schizophrenia, but psychosocial 
dysfunction is not uncommon [2] and 30-60% of BD patients have detectable levels of social 
impairment in both occupational and social realms [3]. In a recent study (N=1656) of 
outpatients with BD, 64% had achieved clinical- but only 34% achieved functional recovery 
after 2 years [4], in line with previous studies demonstrating lack of functional recovery 
despite syndromal remission [5-7]. The areas most negatively affected appear to be social 
relationships and family life. Despite similar levels of education as the general population 
[8], BD patients are also reported to have lower social and occupational functioning [9], 
including lower annual income, and a higher risk of receiving disability pension or being 
unemployed [8,10]. The annual number of lost work days is also higher than for persons with 
major depressive disorder [11,12].  
 
The factor most commonly associated with social dysfunction appears to be syndromal- or 
subsyndromal depressive symptoms [13-20]. Number of previous depressive episodes seems 
negatively related to impairments of social life, and number of previous manic episodes to 
impairments of work- and family life [21]. In direct comparisons, previous episodes of 
depression appears to be a stronger determinant of outcome than previous episodes of 
mania [3,22,23]. Findings regarding other clinical characteristics, such as age at onset, 
duration of illness, total number of episodes or the presence of psychotic symptoms, are less 
conclusive [9]. 
 
Cognitive dysfunction is an important predictor of social dysfunction in severe mental 
disorders, particularly in schizophrenia where it by many is considered the most significant 
contributor to functional loss [24]. Cognitive dysfunction is also found to be significantly 
136 
 
associated with psychosocial functioning in 6 of 8 studies of euthymic BD patients, and in 5 
of 5 studies of symptomatic BD patients [25]. Deficits in various areas of neurocognition such 
as verbal memory [13,26-28] attention [28], executive functioning [13,26-28] and processing 
speed [17], have been linked to social dysfunction or to prediction of long-term functional 
outcome in BD. The longitudinal relationship is however unclear, since most studies are from 
chronic patient samples, and it is possible that both depression and cognitive dysfunction 
occur more frequently later in the course of BD. To better investigate mechanisms behind 
social dysfunction in BD, separating clinical factors from the confounding influence of failed 
treatments and social marginalization, we need studies following patients from their first 
treatment contact. Studies of social dysfunction in early phase BD are however very rare, 
and the pioneering studies comprise mainly hospitalized and/or psychotic patients and do 
not include measures of neurocognition [29,30]. The recent Systematic Treatment 
Optimization Program for Early Mania (STOP-EM) project found significantly social- and 
neurocognitive dysfunction in BD patients  even at first treatment contact [16], and a six 
month follow-up of clinically stable patients (N=45) found that baseline verbal learning and 
memory was robustly associated with functional- but not clinical outcome in this group [31]. 
 The current study is based on an extensively clinically, neurocognitively and 
functionally characterized cohort of patients coming to their first treatment for a manic 
episode (i.e. first contact mania patients). Thereby including both patients experiencing their 
first lifetime manic episode lifetime, in addition to patients with one or more previously 
untreated manic episodes.  
Our main aims are to provide a comprehensive characterization of social functioning using 
both clinician-rated and self-report measures and to examine the relationship between 
current social functioning (self-reported and clinician-rated), and neurocognition, age at 
onset, premorbid adjustment and current clinical symptoms.  
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Materials and methods 
 
Participants 
Participants were recruited consecutively to the Thematically Organized Psychosis (TOP) 
Study from psychiatric inpatient and outpatient units at hospitals in the Oslo area. Patients 
were eligible for this particular study if they met the diagnostic criteria for DSM-IV [32] BD 
type I and received their first adequate treatment for a manic episode (i.e. defined as first 
contact mania). Patients who had experienced previously untreated manic episodes, or had 
experienced and/or received treatment for a major depressive episode could also be 
included in the study.  Some acute patients were unable to give informed consent at first 
contact due to severe and disruptive symptoms, but were given the opportunity to enter up 
to one year after the start of first treatment. A total of 55 patients met these inclusion 
criteria. In the analysis, this patient group was divided into two groups: the First Manic 
episode group (FM), had experienced only one manic episode, and the Previous Manic 
episodes group (PM), had experienced previous untreated manic episodes. Healthy control 
(HC) participants were randomly selected from national statistical records from the same 
catchment area as the patients and contacted by letter inviting them to participate. HC 
participants were excluded if they or any close relative had a lifetime history of a psychiatric 
disorder (schizophrenia, BD and major depression), or if they had substance abuse or 
dependency in the last six months. For the purpose of this study, consecutive HC participants 
were matched in a ratio of 2:1 to each patient based on age, gender and education. 
Exclusion criteria for all groups were a history of head injury requiring hospitalization, 
presence of a neurological disorder, an unstable or uncontrolled medical condition that 
interferes with brain function, IQ below 70 and age outside the range of 17-60 years. The 
participants also had to have Norwegian as their first language or have received their 
compulsory schooling in Norway, in addition to a score of 15 or above on the forced 
recognition trial in the California Verbal Learning Test (CVLT-II) [33] to ensure adequate test 
effort. The study was approved by the Regional Committee for Medical Research Ethics and 
the Norwegian Data Inspectorate. All patients received a complete description of the study 
before giving written informed consent. 
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Clinical assessment 
Trained psychiatrists and clinical psychologists carried out clinical assessment. Diagnosis, age 
at onset, number of previous mood episodes and information about lifetime presence of 
psychotic symptoms were based on the Structured Clinical Interview for DSM-IV Axis I 
disorders (SCID-I) [34] and available medical records. Inter-rater reliability for diagnosis had 
an overall kappa-score of 0.77 (95% CI [0.60, 0.94]) [35]. The level of current 
symptomatology was assessed by the following scales: Current depressive symptoms were 
rated using the Inventory of Depressive Symptoms-Clinician rated (IDS-C) [36], current manic 
symptoms by the Young Mania Rating Scale (YMRS) [37], and current positive and negative 
symptoms by the Positive And Negative Syndrome Scale (PANSS) [38].  
  
Assessment of social functioning   
 
The Social Functioning Scale (SFS) [39] is a self-administered questionnaire consisting of 76 
items arranged into seven subscales. Each subscale is standardized to a scaled score (SS) 
with a mean of 100 and standard deviation of 15, based on a sample of 334 outpatients with 
schizophrenia [39]. The SFS total score is the mean of the seven subscale SSs. High scores 
indicate a better performance than low scores. The seven subscales are: (1) Withdrawal 
(time spent alone, initiation of conversation, social avoidance); (2) Interpersonal behavior 
(number of friends, having a romantic partner, quality of communication); (3) Pro-social 
activities (engagement in common social activities, e.g. going to the cinema); (4) Recreation 
(engagement in common hobbies and interests); (5) Independence-competence (the ability 
to perform skills necessary for independent living, like shopping for groceries, doing laundry 
etc.); (6) Independence-performance (the actual performance of those same skills); (7) 
Employment (engagement in productive employment or a structured program of daily 
activity). The Norwegian version of the SFS is validated for use in both patients with 
schizophrenia and those with BD [40]. The scale was administered to all participants as part 
of the neuropsychological examination, and participants were given instruction on how to 
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complete the questionnaire by a trained psychologist, and were allowed to ask questions if 
they were uncertain of the meaning of any specific items. In addition to the SFS, the Global 
Assessment of Function (GAF) split version (GAF-Function and GAF-Symptom) [41] was used 
to measure clinician-rated social functioning. The scale is divided into ten equal intervals 
ranging from 1 to 100, where a score of 100 represents superior functioning. For the 
purpose of this study, only the function scale (GAF-F) was used as a measure of global social 
functioning. We used the Premorbid Adjustment Scale (PAS) to measure premorbid social 
functioning [42]. The PAS is designed to evaluate the level of functioning in four major areas 
during different periods of the subject’s life, based on self-report: (1) social accessibility - 
isolation, (2) peer relationships, (3) ability to function outside the nuclear family and (4) 
capacity to form intimate socio-sexual ties. Items evaluating age-appropriate functioning in 
these areas are repeated for each period of the subject’s life (Childhood < 11 years; Early 
Adolescence, 12-15 years; Late Adolescence, 16-18 years; and Adulthood > 19 years). Scores 
range from 0-6 where zero represents the best possible functioning. For the analyses, PAS 
scores were divided into two domains, Academic and Social, and for each domain, we 
discriminated between the initial level of functioning (childhood scores) and the change in 
level of functioning (difference between last premorbid score and initial score) [43]. 
 
 
Neurocognition 
 
Psychologists trained in standardized neuropsychological testing carried out the 
neuropsychological assessment. A three-hour test battery including measures previously 
found to be sensitive to dysfunction in severe mental disorders [44,45] was administered in 
a fixed order with two breaks in between.  
Verbal memory was tested with the Logical Memory test (LM-I) from the Wechsler Memory 
Scale-III (WMS-III) [46] and the Total List A 1-5 score from the California Verbal Learning 
Test-II (CVLT-II) [33]. Processing speed was assessed with the Digit Symbol test from the 
WAIS-III [47]. Working memory was assessed with Digit Span (forward and backward task) 
from the WAIS-III [47], and with d-prime (d’) from the Bergen n-back task [48]. Verbal fluency 
was measured with the Letter Fluency and Category fluency from the Verbal Fluency Test in 
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the D-KEFS battery [49]. Interference control was measured by the Inhibition and the 
Switching subtest from the Color-Word Interference Test in the D-KEFS battery [49]. Raw 
scores were reported for all tests. Analysis from our previous work [50] has shown significant 
differences between the two BD groups and the HC group on three of the ten chosen 
measures: Digit symbol, Digit span backward and the Color-Word Inhibition subtest, with the 
HC group performing better in all three.  The clinical group also showed clinically significant 
cognitive impairment on all ten neuropsychological measures, defined as neurocognitive 
scores 1.5 SD below the average of the healthy control group. On average 17% of the two BD 
patient groups combined had clinically significant cognitive impairment. 
 
Statistical analysis 
The Statistical Package for the Social Sciences (SPSS for Windows, version 16.0, SPSS Inc., 
Chicago, IL, USA) was used for all statistical analysis. Univariate analysis of variance (ANOVA) 
with Scheffès post hoc tests or Chi-square tests were used to compare FM, PM groups, and 
independent samples t-tests or Chi-square tests to compare the  FM and PM groups. Due to 
small sample sizes and limited group differences the FM and PM groups were combined for 
the last sets of analyses. Non-parametric correlations (Spearman’s rho) were used to assess 
the relationship between self-rated (SFS) and clinician-rated (GAF-F) social functioning with 
clinical and neurocognitive variables. Multiple regression analysis was carried out to explore 
the independent contribution of neurocognition and current symptomatology to self-rated 
(SFS) and clinician-rated (GAF-F) psychosocial function. We here included clinical and 
neurocognitive variables with an ρ > .20 to at least one of the functional measures in 
bivariate correlations. Clinical and premorbid variables were entered in block 1 and 
neurocognitive measures in block 2. The effect of insight on the relationship between SFS 
Total score and GAF-F was assessed using partial correlations and the PANSS G12 subscore 
as a measure of insight.  
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Results 
 
Clinical and functional characteristics  
 
Demographic characteristics of the FM, PM and HC groups are presented in table 1 (TABLE 1 
IN HERE). Measures of symptom severity and clinician-rated social functioning for the clinical 
groups (FM and PM) are presented in table 2 (TABLE 2 IN HERE). Both clinical groups showed 
good premorbid functioning (low PAS scores) with little change during the premorbid period, 
and with no significant differences between the groups. The median (min-max) age at onset 
for the FM group was 23 (11-53) years and 17 (10-37) years for the PM group (p < 0.05). At 
the time of assessment, both clinical groups had a moderate symptom load and functional 
impairment, as indicated by the GAF-S and the GAF-F levels. The groups also had low levels 
of current psychotic (PANSS-P), negative (PANSS-N) or manic (YMRS) symptoms. The median 
IDS-C score indicated that the patients were mildly depressed. The PM group had, as 
expected, significantly more depressive, manic and psychotic episodes as well as more 
hospitalizations and a longer treatment delay before first treatment compared to the FM 
group. The majority of participants were single, with no significant group differences 
regarding marital status. The groups however differed significantly on work ability; while the 
majority of FM participants were working or studying, the majority of the PM participants 
were on medical leave. 
 
 
  Self-rated social functioning in BD and HC participants 
 
There were significant group differences between healthy controls and the two clinical 
groups for all SFS sub scales and the total score (Table 3) (TABLE 3 IN HERE). In addition, the 
FM and PM groups differed significantly from each other for the Independence-Competence, 
Prosocial Activities and Employment sub-scales, as well as the SFS Total score. The PM group 
rated themselves as less competent in performing independent living skills, participated less 
in social activities, were less likely to be engaged in full-time employment and had a lower 
overall SFS score compared to the FM group. Effect sizes were small to medium, with the 
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largest effect sizes for Independence-competence, Employment and SFS Total score. There 
was a small, but statistically significant, association between the two measures of social 
functioning, the SFS Total score and GAF-F (ρ=0.29, p=0.05). Controlling for insight had little 
effect on the relationship between the SFS Total score and the GAF-F.  
 
 
 
The relationship between social functioning and clinical and neurocognitive measures. 
 
A total of seven clinical variables correlated significantly (ρ > .20) with at least one measure 
of social functioning (four for the SFS and three for the GAF-F) (Table 4) (TABLE 4 IN HERE). 
For the SFS, these variables included cannabis use, current depression and number of 
depressive episodes. There was also a significant correlation between age at onset and SFS, 
indicating that better functioning was associated with later onset of BD. There were no 
significant associations between any measures of premorbid social adjustment and current 
social functioning measured by the SFS. In addition, the level of current PANSS positive-, 
depressive- and manic symptoms were all statistically significantly associated with the GAF-
F. There were no significant correlations between any measures of premorbid social 
functioning and the GAF-F.  
Neurocognitive variables (raw scores’ mean (SDs)) are presented in table 5 (TABLE 5 IN 
HERE). There were no statistically significant correlations between neither self-rated social 
functioning (SFS Total score) nor clinician-rated social functioning (GAF-F) and 
neuropsychological test performance. Three of the neurocognitive tests representing the 
domains of processing speed and working memory correlated ρ > .20 with SFS Total score or 
GAF-F, and were chosen for further exploration in multiple regression analysis. An inspection 
of the partial correlation suggested that controlling for group membership (FM, PM) would 
not affect the relationship between clinical variables and self- or clinician-rated social 
functioning. The same result was also found for the neurocognitive variables.  
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Clinical and cognitive predictors of baseline social functioning 
 
 (TABLE 6 IN HERE). For the SFS, current level of depression (IDS-C) was the only clinical 
characteristic that remained in the final model (Table 6). Neither premorbid social functional 
level, current cannabis use, current psychotic/manic symptoms nor number of depressive 
episodes had any statistically significant influences after controlling for current levels of 
depression. Of the three selected neurocognitive variables, only Digit symbol test had a 
statistically significant influence in the multiple regression analyses, indicating that good 
processing speed was related to lower self-rated social functioning. Neither the Verbal 
fluency letter subtest nor the Digit span backward subtest contributed. Analysis of the same 
sets of variables with social functioning (GAF-F) showed that only the PANSS-Positive scale 
contributed significantly to the model. Adding group membership (FM vs PM) to the final 
step of the analysis did not change individual contributions, but only had a significant effect 
on self-rated social functioning but not on clinician-rated social functioning. 
 
 
 
 
Discussion 
 
The main finding of the study is that social dysfunction is present in patients with BD I 
already at their first treatment contact. Both the FM and PM groups scored significantly 
lower on all subscales of the SFS compared to healthy controls. In addition, PM patients 
rated themselves significantly lower than FM patients for the Independence-Competence, 
Prosocial activities and Employment subscales, had significantly lower SFS Total scores and 
also poorer occupational functioning. This confirms and expands findings from previous 
studies of various BD subgroups [3,4,16,51], with data of early signs of social dysfunction and 
of increasing dysfunction with increasing number of untreated episodes. 
The main predictors of reduced functioning in the patient groups were clinical symptoms, in 
particular current depression that had the strongest independent contribution in 
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multivariate analyses. Neurocognitive functioning, with the possible exception of processing 
speed as measured by the Digit symbol test, did not appear to play an important role as a 
contributor to differences in social functioning, at least at this stage of the disorder. That the 
PM group tended to rate themselves as more impaired than the FM group patients with a 
first episode, may not necessary relate to the negative influence of manic episodes since the 
groups also differed concerning several other important clinical characteristics. The PM 
group had a longer treatment delay before first treatment, an earlier age at onset and more 
previous depressive and psychotic episodes. Both age at onset and number of depressive 
episodes have previously been found associated with reduced social functioning [52-54], 
with indication that the greatest decrease in function occurs relatively early in the course of 
illness [54]. 
Ongoing depressive symptoms were significantly associated with both lower self- and 
clinician-rated social functioning. The relationship between current depressive or subclinical 
depressive symptoms and social dysfunction in BD has also been consistently reported in 
previous studies [13-17,19,28]. Manic and psychotic symptoms were however mainly 
associated with lower clinician-rated social functioning. These findings are in line with 
previous studies of more chronic patients reporting increasing family friction already at the 
stage of hypomanic symptoms [55] and stepwise progression in disability with each 
increment of elevated mood [56]. In line with previous studies reporting an association 
between social dysfunction and substance use disorders [57,58] or excessive substance use 
[59], we found a significant association between life-time cannabis use and poorer self-rated 
social functioning in bivariate, but not in multivariate analyses. We also did not find any 
association between premorbid adjustment and social functioning, most probably because 
the patient group did not show any sign of premorbid dysfunction. The few previous studies 
on premorbid functioning in BD are conflicting, with findings both of reduced premorbid 
adjustment [60] and of normal adjustment [61]. Our findings support the notion that 
dysfunction in BD primarily develops in connection with clinical episodes and not earlier, as 
often seen in schizophrenia. 
 
We found no significant correlations between neurocognition and self- or clinician-rated 
social functioning in bivariate analyses, in contrast to previous findings [13,17,26-28], 
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including a study of previously treated BD patients from our own study group [44]. Our 
current findings are however more in accordance the only previous study of first-episode BD 
[31], that found a lack of associations between baseline neurocognition and concurrent 
baseline psychosocial functioning in newly diagnosed patients with BD. Baseline cognitive 
functioning however predicted 6-month functional outcome. One possible explanation for 
the lack of association at this point of time is that the relatively high symptom levels during 
the first treatment phase may confound the relationship between cognition and baseline 
social functioning. Our finding that correcting for current levels of depression actually 
revealed a significant relationship between processing speed (Digit symbol test) and SFS 
total score not observable in the bivariate analysis may be a sign of this. The particular 
finding showed that both high current levels of depression and good processing speed had 
independent contributions to self-rated social dysfunction.  
Our findings thus point to different predictors of self- and clinician rated social dysfunction. 
We have previously shown that the SFS measures slightly different aspects of social 
functioning than the GAF-F [40], as indicated by relatively low levels of association between 
the two measurements. The validity of self-report assessments in severe mental illness has 
been questioned [62]. Studies indicate that self-reports and reports by others agree more in 
the report of observable aspects such as functioning, than of psychological aspects where 
others actually tends to underestimate the severity [63]. We did not find that level of insight 
had any significant effect on the strength of the relationship between the SFS and the GAF-F, 
supporting the view that the lack of congruence is less a question of validity as of differences 
in underlying constructs. In line with this we conclude that since clinician-rated functioning 
relies more on observable aspects it also appears to be more influenced by severe 
psychopathology such as manic- or psychotic symptoms, while self-rated social functioning 
appears to be influenced by more subtle disturbances.  
Patients with BD display comparative negative cognitive styles during depressive episodes to 
patients with unipolar depression. This includes low self-esteem, negative self-beliefs, self-
blaming attributions and concerns about the need for achievement [64], which may cause 
depressed individuals to view themselves as more poorly functioning. Depressive periods are 
also characterized by decreased energy and social withdrawal. The basis for an association 
between good processing speed and lower self-rated social functioning can thus be 
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mediated by higher expectations and/or better awareness of own social functioning in 
persons with good cognitive functioning. 
 
This study has several strengths and limitations. Strengths: This is one of the very first 
studies to examine the relationship between social functioning, clinical characteristics and 
neurocognition in a first contact BD cohort. We used reliable and valid self-report 
instruments that capture varied aspects of current and premorbid social functioning to 
measure social functioning in BD in addition to standard clinician-rated functional measures. 
Limitations: Patients were not euthymic as 60% of patients were at least mildly depressed, 
but since it was our goal to include patients as early in their disease course as possible i.e. in 
a period  with relatively high levels of symptomatology, settling for complete euthymia 
would have delayed assessments considerably. The number of previous mood episodes was 
determined retrospectively and as always with retrospective reporting, there is a potential 
for bias although efforts were made to confirm through medical records. 
 
 
 
Conclusion: 
Impairment of social functioning is present in patients with BD as early as after their first 
treated manic episode. Patients with previous mood episodes and a longer treatment delay 
reported more social impairment and were less likely to be engaged in full-time employment 
or education than the rest of this first-contact group. Clinical symptoms were the most 
significant predictors of both self-rated and clinician-rated social functioning, with current 
depression associated with self-rated function and psychotic symptoms with clinician-rated 
function. Processing speed had a significant influence on social functioning, while other 
neurocognitive measures did not appear to play a significant role in social functioning at this 
point of time.  
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